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A series of studies has been carried out, examining the effect 
and mode of action of various compounds on the haem biosynthetic pathway.
a) (1 ) Allyl isopropyl acetamide (AIA) (300 mg/kg) elevated the activity
of rat hepatic Saminolaevulic acid (ALA) synthetase activity tenf cld, 
and also elevated AL1 dehydrase activity and porphyrin and porphyrin 
precursor excretion.
(2) Animal sex had no significant effect on hepatic ALA synthetase 
activity.
(3) In the neonatal period of development hepatic ALA synthetase has
a significantly higher activity than in the adult rat.
(4) Starvation of rats for 24 hours, with water ̂ad lib' significantly
elevates hepatic ALA synthetase activity.
(5) Vitamin E. significantly depresses porphyrin precursor and 
porphyrin excretion in rats intoxicated with AIA but has no significant 
effect on enzyme activities.
b) (I) Some barbiturates, when given to rabbits, cause a rise in urinary
coproporphyrin excretion while others, suspected of provoking acute 
attacks of porphyria in man, do not. To investigate this anomaly, the 
levels of hepatic enzymes occurring early in the biosynthetic pathway 
have been examined in rats treated with barbiturates.
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(2) Of the nine barbiturates tested all significantly raised the 
hepatic level of ALA synthetase activity in the rat. This elevation 
was abolished by the antibiotics, cyclohexiinide and actinomycin D.
(3) These barbiturates may be classified into four significantly 
different groups, which correspond to the groups of the earlier 
classification based on urinary coproporphyrin excretion.
(4) The chemically related compounds, cyanuric acid, glutethimide and 
pentazocine, also elevated hepatic ALA synthetase activity in the rat.
(5) It is suggested that these results show a direct reason for 
contraindication of any barbiturates, glutethimide and pentazocine in 
porphyria.
(6 ) The mechanism of this elevation of enzyme activity by these drugs 
is discussed.
c) (1) The activity of Saminolaevulic acid synthetase is significantly
elevated in the liver of rats and the activity of Saminolaevulic acid 
(ALA) dehydrase is significantly depressed in the blood of man and rats 
intoxicated with ethanol.
(2) This depression of ALA dehydrase activity follows closely on the 
elevation of blood ethanol and returns to normal 'pari passu' with the 
ethanol level.
(3) In rats intoxicated with ethanol there is a significant depression 
of ALA dehydrase activity in the liver and kidney.
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(4) A scheme is proposed whereby an increase in the intracellular 
redox potential by ethanol increases sulphydryl cofactor concentrations 
leading to an inhibition of ALA dehydrase activity.
d) (1 ) A series of twenty Ci8 , and ^ 2 1  steroids have been examined for 
their effects on rat hepatic ALA synthetase activity.
(2) The following: Dehydroepiandrosterone, 17 hydroxy-Pregnenolone,
Androstenedione, Androstenediol and Etiocholanolone significantly elevated 
hepatic ALA synthetase activity in rats.
(3) Dehydroepiandrosterone and its sulphate were effective in elevating 
ALA synthetase activity yet the acetate and glucuronide forms were 
ineffective in raising activity.
(4) The antibiotics Actinomycin D and Cycloheximide abolished this DHA 
elevation of activity at all times during the induction, thus suggesting 
that this elevation of enzyme activity is due to a de novo synthesis of 
enzyme protein.
e) A stud}' has been carried out on four patients with hereditary 
coproporphyria, two patients in attack and two in remission;
(1 ) All of the patients showed typical excessive excretion of urinary and 
faecal coproporphyrin with elevated excretion of porphyrin precursors in 
attack.
(2) Both patients in attack had elevated blood ALA dehydrase activity 
and one a highly elevated hepatic ALA synthetase activity.
(3) Both patients in attack had elevated urinary excretion of certain 
17 oxosteroids.
These results and their relevance to the control and pathogenesis of the haem 
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A series of studies has been carried out, examining the effect 
and mode of action of various compounds on the haem biosynthetic pathway.
a) (1 ) Allyl isopropyl acetamide (AIA) (300 mg/kg) elevated the activity
of rat hepatic Saminolaevulic acid (ALA) synthetase activity tenf cld, 
and also elevated ALA dehydrase activity and porphyrin and porphyrin 
precursor excretion,
(2) Animal sex had no significant effect on hepatic ALA synthetase 
activity.
(3) In the neonatal period of development hepatic ALA synthetase has
a significantly higher activity than in the adult rat.
(4) Starvation of rats for 24 hours, with water ’ad lib’ significantly
elevates hepatic ALA synthetase activity.
(5) Vitamin E. significantly depresses porphyrin precursor and 
porphyrin excretion in rats intoxicated with AIA but has no significant 
effect on enzyme activities.
b) (1 ) Some barbiturates, when given to rabbits, cause a rise in urinary
coproporphyrin excretion while others, suspected of provoking acute 
attacks of porphyria in man, do not. To investigate this anomaly, the 
levels of hepatic enzymes occurring early in the biosynthetic pathway 
have been examined in rats treated with barbiturates.
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(2) Of the nine barbiturates tested all significantly raised the 
hepatic level of ALA synthetase activity in the rat. This elevation 
was abolished by the antibiotics, cycloheximide and actinomycin D.
(3) These barbiturates may be classified into four significantly 
different groups, which correspond to the groups of the earlier 
classification based on urinary coproporphyrin excretion.
(4) The chemically related compounds, cyanuric acid, glutethimide and 
pentazocine, also elevated hepatic ALA synthetase activity in the rat.
(5) It is suggested that these results show a direct reason for 
contraindication of any barbiturates, glutethimide and pentazocine, in 
porphyria.
(6 ) The mechanism of this elevation of enzyme activity by these drugs 
is discussed.
c) (1) The activity of Saminolaevulic acid synthetase is significantly
elevated in the liver of rats and the activity of Saminolaevulic acid 
(ALA) dehydrase is significantly depressed in the blood of man and rats 
intoxicated with ethanol.
(2) This depression of ALA dehydrase activity follows closely on the 
elevation of blood ethanol and returns to normal 'pari passu' with the 
ethanol level.
(3) In rats intoxicated with ethanol there is a significant depression 
of ALA dehydrase activity in the liver and kidney.
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(4) A scheme is proposed whereby an increase in the intracellular 
redox potential by ethanol increases sulphydryl cofactor concentrations 
leading to an inhibition of ALA dehydrase activity.
d) (1 ) A series of twenty Cjg, ^19 and ^2\ steroids have been examined for 
their effects on rat hepatic ALA synthetase activity.
(2) The following; Dehydroepiandrosterone, 17 hydroxy-Pregnenolone, 
Androstenedione, Androstenediol and Etiocholanolone significantly elevated 
hepatic ALA synthetase activity in rats.
(3) Dehydroepiandrosterone and its sulphate were effective in elevating 
ALA synthetase activity yet the acetate and glucuronide forms were 
ineffective in raising activity.
(4) The antibiotics Actinomycin D and Cycloheximide abolished this DHA 
elevation of activity at all times during the induction, thus suggesting 
that this elevation of enzyme activity is due to a de novo synthesis of 
enzyme protein.
e) A study has been carried out on four patients with hereditary 
coproporphyria, two patients in attack and two in remission;
(1 ) All of the patients showed typical excessive excretion of urinary and 
faecal coproporphyrin with elevated excretion of porphyrin precursors in 
attack.
(2) Both patients in attack had elevated blood ALA dehydrase activity 
and one a highly elevated hepatic ALA synthetase activity.
(3) Both patients in attack had elevated urinary excretion of certain 
17 oxosteroids.
These results and their relevance to the control and pathogenesis of the haem 
biosynthetic pathway are discussed.
INTRODUCTION
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THE HAEM BIOSYNTHETIC PATHWAY
The initial elucidation of the early steps of this biosynthetic 
pathway was a result of a set of brilliant isotopic tracer studies. These are 
described by Shemin (1955) and laid the foundation for all further work in 
porphyrin biochemistry. Because of this and other studies the general pathway 
of Haem biosynthesis is now well understood.
4Prior to 1946 the manner of biosynthesis of the porphyrins had been 
speculatory, but in that year Shemin and Rittenberg demonstrated a specific 
labelling of Haem by glycine. The initial stage of the pathway is the 
condensation of glycine and succinyl CoA (Shemin & Kumin, 1952) by ALA 
synthetase (ALA.S) (Pig. 1.). The cofactors for this reaction are pyridoxal 
phosphate (Schulman & Richert, 1956) and ferrous iron (Brown, 1958). The 
pyridoxal phosphate activates the methylene group of glycine preliminary to 
Schiff Base formation. This glycine and 'activated' succinate, succinyl CoA, 
then condense to formOCamino pketo adipic acid, which being a pketo acid readily 
decarboxylates to form Saminolaevulic acid (ALA).
To unify the reactions of glycine, Shemin & Russell, (1953) and Shemin 
(1955) postulated a series of reactions, the succinate-glycine cycle, now called 
the 'Shemin' cycle, whereby glycine in addition to its utilisation for ALA 
synthesis and porphyrin synthesis was also used to provide a single OC carbon 
fragment in the synthesis of the ureido group of purines and the p carbon of 
serine, the remaining residue being reconverted to succinate. Although some 
experiments (Nemeth et al, 1957; Braunstein et al, 1964) support the existence of 
this cycle, its general metabolic significance remains to be evaluated. The 
enzyme which catalyses the conversion of ALA to 4.5 dioxovaleric acid, alanine 
dioxovalerate transaminase, has been demonstrated in Rhodopseudomonas spheroides 
(Neuberger & Turner, 1963) Bacterium diphtheriae (Bagdasarian, 1958) and in
ALA SYNTHETASE 
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mammalian tissues (Kowalski et al, 1957). However, in the work on R. spheroides 
it was found that the reverse reaction was more easily studied because the 
equilibrium lay to the side of ALA, and in consequence this pathway must be of 
small importance in this biosynthetic sequence. (Gibson et al, 1961). , although 
other intermediates of this type have recently described by Shigesada et al (1970) 
from Rhodospirilium rubrum.
The monopyrrole precursor of the porphyrins^porphobilinogen (PEG),was 
first isolated from porphyria urine by Westall in 1952, and its structure 
determined by Cookson and Rimington (1953, 1954). The formation of PBG represents 
the first committed step in porphyrin biosynthesis. It is formed by the 
condensation of two molecules of ALA with elimination of water by the enzyme ALA 
Dehydrase (ALA.D) which was first described by Dresel & Falk (1953) and then by 
Gibson, Neuberger & Scott. (1955).
The subsequent steps of this pathway involve formation of the 
tetrapyrrole porphyrin ring from four units of PBG followed by the successive 
decarboxylation of the octacarboxylic porphyrin thus formed to the dicarboxylic 
porphyrin, protoporphyrin. The initial step of this sequence is catalysed by 
porphobilinogen deaminase which condenses the porphobilinogen monomer units into 
a polymer of indeterminate length, poly N. pyrryl methane. This polymer is then 
cyclised into uroporphyrinogen units, a tetrapyrrole (Bogorad, 1958a and b; 
Cornford, 1964). If the enzyme uroporphyrinogen isomerase or synthetase is present 
this reaction produces the biologically viable series 3 isomer; if not, it produces 
the series 1 isomer. In natural systems the series 1 isomer cannot be converted 
into protoporphyrin and will only produce uroporphyrin 1 and copfoporphyrin 1 
which are excreted in the urine.
Coproporphyrinogen the subsequent substance on the pathway is 
produced by the successive decarboxylation of uroporphyrinogen by uroporphyrinogen 
decarboxylase with the series 3 isomer being decarboxylated twice as rapidly as 
the series 1 isomer (Mauzerall & Granick, 1958).
By the action of the mitochondrial enzyme coproporphyrinogen oxidase 
and decarboxylase the tetracarboxylic coproporphyrinogen 3 is converted to 
protoporphyrin 9 through the intermediate tricarboxylic porphyrinogen and 
dicarboxylic porphyrinogen stages. It is these enzymes that cannot handle the
series 1 isomer (Batlleetal 1965: Sano & Granick, 1961).
The final enzyme of the pathway is Haem Synthetase or Ferrochelatase 
(Goldberg, 1956; Labbe & Hubbard, 1960; Porra & Jones, 1963) which catalyses the 
insertion of ferrous iron into protoporphyrin to form Haem. This whole sequence, 
shown overleaf (fig.2) is reviewed in detail by Goldberg & Rimington (1962).
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Pig. 2. The Haem Biosynthetic Pathway.
ALA SYNTHETASE
ALA synthetase is the initial and rate limiting enzyme of haem 
biosynthesis (Granick & Urata, 1963) and is the main subject of this study. By 
virtue of its properties, a short half life, 1 hour in mammalian systems 
(Marver et al, 1966; Stein et al, 1970) 4-6 hours in avian systems (Granick 
1966) with an equally short half life of its messenger RNA; low endogenous 
activity, and its position at the beginning of a biosynthetic sequence, it might 
be expected that this enzyme would be one of the principal controlling 
influences on the haem biosynthetic pathway.
One endogenous controlling factor of this enzyme is Haem. End 
product repression of ALA.S by haem or haemin is well characterised. In 
bacteria, Lascelles (1960) and Burnham & Lascelles (1963) showed that haem 
participates in end product repression, whilst in eucaryotic cells a similar 
effect occurs (Granick, 1966; Marver et al, 1968). Welland et al (1966) showed 
that haemin inhibited or repressed ALA.8  in liver at a concentration of 10~% 
and Vavra (1967) showed the same using chicken mitochondria. Other authors have 
been unable to detect this effect (Neuwirt et al, 1969 a and b) but this may in 
part be due to the relative crudity of their systems and to the presence of 
protein, since Scholnick et al (1969) have shown that haem is bound non- 
specifically by a number of proteins. ALA.8  and Haem synthetase are mito­
chondrial enzymes (Granick & Levere, 1964) and although it had been suggested 
that compartmentalisation is a possible control point in the pathway there is 
little evidence that compartmentalisation is a controlling factor (Sano &
Granick, 1961). Scholnick et al (1969) demonstrated Cytoplasmic ALA.S in the 
liver cytosol and suggested that it was in transit to the mitochondrion.
This is quite conceivable since it is possible that the enzyme is synthesised 
in the cytosol on the rough endoplasmic reticulum and transported from there
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to the mitochondrion. This cytoplasmic enzyme is probably inactive since
there is no extramitochondrial supply of Succinyl CoA in mammalian cells
(Granick & Urata, 1963). The presence of the cytoplasmic enzyme could
explain the discrepancy between the half lives of 1 hour for ALA.S. and
about 7 days for the bulk of mitochondrial protein (Schimke et al, 1968;
Druyan et al, 1969), McKay et al (1968, 1969) showed the mitochondrial enzyme
to be positioned similarly to two other mitochondrial matrix enzymes, malate
dehydrogenase and glutamate dehydrogenase and have concluded that it is also a
mitochondrial matrix enzyme.
Within the mitochondrion various other aminoketones are synthesised 
from glycine other than ALA (Urata & Granick, 1963). Glycine combines with 
other compounds in their activated coenzyme A forms such as acetyl CoA to 
form these aminoketones. The general reaction for this series of reactions may 
be represented as :
B CO. 8 . CoA.+ CH, . NH,. COOH— 00. C H _ N H . +  C 0 „ + H S C 6 À  
^ ^ PAL.P 2 2 2
For ALA formation the enzyme is of course ALA.S, this being a different enzyme to 
aminoacetone synthetase although it has some aminoacetone synthetic activity 
(Dale, 1969) and the activated compound is succinyl CoA. This reaction was 
demonstrated in chicken erythrocytes by Gibson et al, (1958), and in R. 
spheroides by Kikuchi et al (1958). In addition to the formation 
of ALA, the other aminoketone produced in quantity is aminoacetone which 
uses as substrate Acetyl CoA (Nemeth et al, 1958). In this reaction sequence, 
pyridoxal phosphate (PAL.P) activates the glycine by forming a Schiff base 
with it. This is followed by condensation to a pyridoxalimine which 
decarboxylates whilst still on the pyridoxal with subsequent detachment of the 
6 aminolaevulic acid. Hie Schiff base that is formed would be more stable 
when chelated by a metal ion, and indeed ferrous iron seems to fill this role. 
Brown, (1958) showed that ferrous iron at a concentration of 10 depressed 
ALA.8  activity which activity was restored on storage, presumably due to the
oxidation of the ferrous to ferric iron. These results were confirmed by 
Morrow et al (1969) who further showed that ferrous iron at a lower 
concentration, 1 0 activated the enzyme and that ferric iron, at all 
concentrations used, caused a small depression of activity, although Stein 
et al (1970) have shown a synergistic effect of ferric citrate and AIA on 
ALA. S induction. In the scheme shown on the opposite page it is proposed 
that ALA.S is joined to the glycine-pyridoxal phosphate complex by an imine 
bond to the glycine nitrogen. The rest of the scheme is as described 
previously (fig.3.).
The Colourimetric determination of ALA depends on the formation of 
an'Ehrlich’s positive' pyrrole. This is achieved by a condensation with 
acetylacetone followed by complexing of the OC carbon of the pyrrole thus formed 
with Ehrlich's aldehyde reagent (p dimethyl amino benzaldehyde) (Mauzerall & 
Granick, 1956). This is of consequence since in biological systems other 
interfering aminoketones are present, principally aminoacetone, which also
forms a pyrrole with acetyl acetone. This factor is taken into account in both 
ALA.8  assays used in this work. In both assays conditions are such that they 
minimalise aminoacetone production whilst optimalising ALA production, and in 
one assay there is a further step which separates the pyrroles of these compounds 
by ion exchange chromatography.
At the beginning of the pathway, there is a possible relationship 
between the activities of ALA.S and succinyl CoA synthetase (E.G. 6 . 2.1.5.).
This enzyme does not properly lie on the pathway but supplies succinyl CoA from 
the citric acid cycle which is essential to the working of the pathway. Most 
of the succinyl CoA required for this reaction is generated from succinate and 
coenzyme A in the presence of NADPH by the enzyme succinyl CoA synthetase 
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Pig. 3 Postulated Mechanism of Action of ALA synthetase.
E. in the figure represents the enzyme.
mechanisms for the formation of succinyl CoA from propionyl CoA through 
methylmalonyl CoA (Stadtman et al, 1960) and from acetoacetyl CoA via a CoA 
transferase to succinate (Stern et al, 1956) have been described in mammalian 
systems but their physiological relevance to ALA formation is uncertain. It 
was found that malonate used to inhibit succinate dehydrogenase, and thus 
leading to an accumulation of succinate, led to a 60% increase in ALA production 
(Miyakoshi & Kikuchi, 1963; Ludwig et al, 1965; Gajdos et al, 1966). This 
suggests that there had been some substrate induction of ALA.S by succinate.
In experimental porphyria however, neither Granick (1966) nor Yoshida &
Ishihara (1969) could find evidence for elevation of this enzyme although 
Labbe et al (1965) had shown a 70% increase in succinyl CoA synthetase.
All Porphyrias, hereditary, acquired and chemical are due to the 
overproduction rather that under-utilisation of porphyrins, and the de novo 
cause of the overproduction is the increased activity of the initial and rate 
limiting enzyme of haem biosynthesis, ALA.S. For this reason I choose to 
define porphyria in this thesis as an overproduction of ALA synthetase, rather 
than defining it in terms of the secondary products of the biosynthetic 
pathway. Thus it might be said that porphyria is due to the induction of 
ALA synthetase activity.
Many compounds have been used in the production of experimental 
porphyria in animals. The first observation was made by Stokvis (1955) who 
observed that excretion of 'haematoporphyrin' could be produced in rabbits by 
Sulphonal. Subsequently one compound described to be porphyrinogenic was 
sedormid (allyl isopropyl acetyl urea) (Schmid & Schwartz 1952). In the 
following years, Goldberg (1953) and Goldberg & Rimington (1954) described 
the compound allyl isopropyl acetamide (AIA) a non-hypnotic derivative of 
sedormid, with a very high porphyrinogenic activity, (fig.4.). This compound
2.ALLYL 2. ISOPROPYL ACETAMIDE
(AIA)
CHg =  CH\CH.
\  /C ---  CH/ \NH- CH  CH/CHg
Fig 4 . Structure of A.I.A.
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is used in this thesis ds a reference point in the measurement of 
porphyrinogenesis. Since then many other compounds have been described 
with porphyrinogenic activity (de Matteis, 1967). In 1966 Granick 
described a method of culture of chick embryo liver on coverslips, whereby 
he was able to screen a large number of compounds for porphyrinogenic 
activity, measuring this activity by the appearance of porphyrin fluorescence 
on the cover slips under ultraviolet light. Of the compounds tested in this 
manner, AIA, Meprobamate, Glutethimide, Methyprylon, Griseofulvin, DDC and some 
steroids were the strongest inducers of fluorescence. He further attempted 
to relate porphyrinogenic activity to their chemical structure, with some 
success.
Most papers subsequent to this quantitate the enzyme activity.
Among the factors implicated in the exacerbation of porphyria is Diet. It was 
found that starvation increases the level of ALA synthetase and that carbohydrate 
feeding of rats made porphyric with AÏA led to an alleviation of the porphyria 
and markedly inhibited the elevation of ALA.8  (Rose et al, 1961; Welland et al, 
1964; Tschudy et al, 1964). This was found to apply also to human porphyria 
(Welland et al, 1964). Simons (1970) describes a twofold induction of ALA.8  
by glucagon. In view of the above dietary work, this may be due to a 
depression of hepatic glycogen levels which is stimulated by glucagon mediated 
by cyclic AMP (Waxman et al, 1966).
In porphyria increased glycogenolysis and glucose consumption leads 
to lowered ATP levels in the cell. Thus Gajdos & Gajdos-Torok (1969) showed 
that the ATP levels dropped before ALA rose and in consequence considered that 
the cellular redox state gave some control over ALA.8  activity. They found 
m  R. spheroides that ATP inhibited the production of porphyrins and further
that this depression was related to the ATP concentration. In rats treated 
with AIA and DDC similar findings were made, and in addition the level of 
NADH rose to a peak three hours after administration of these chemicals.
These facts prompted Cowger and Labbe (1967) to suggest a block in the 
respiratory chain at the level of reoxidation of reduced NADH. There was no 
correlation however between these levels and the levels of porphyrins
"  I*(Gajdos & Gajdos-Torok, 1968; 1969). Thus it was shown that ATP depression
precedes ALA synthetase induction in AIA induced porphyria. In comparison in 
AIA treated rats the induction of ALA.8 in mitochondria could be abolished by 
atractyloside which was used to inhibit the translocation of adenine nucleotides 
across the inner mitochondrial membrane. (Bruni et al, 1964). Finally 
under low oxygen pressure, Gajdos et al (1969) found that DDC porphyrinogenesis 
was depressed. This effect was thought to be due to a stimulation of 
glycolysis with a subsequent elevation of ATP levels which lowered 
porphyrinogenesis and ALA.8  induction.
Since purine dérivâtes have been found to inhibit porphyrin 
biosynthesis (Gajdos & Gajdos-Torok 1963) Adenosine 5 Monophosphate (AMP) has 
been used in the treatment of patients with porphyria, sometimes with 
apparently successful results but it is difficult to theorise on this disease 
because of natural remissions (Gajdos & Gajdos Torok, 1961; Levrat et al, 1963; 
Oaks et al, 1969; Wetterberg, 1964). Recently however in a properly
controlled study,Wetterberg (1970) concluded that it was not possible to show 
any difference in the overall state of health or biochemical tests of porphyria in 
patients receiving AMP or a placebo. In consequence it is doubtful whether 
these nucleotides play an important role in porphyria.
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Bottomley & Smithee (1968) described a method for the measurement of 
ALA synthetase in bone marrow cell mitochondria, in the following year they 
published a paper showing that erythropoietin stimulated ALA synthetase but was 
ineffective in elevating haem synthetase in rabbit bone marrow culture. The 
work of Paul & Hunter (1969) would appear to corroborate this since they 
demonstrated an induction of haem synthesis by erythropoietin in mouse embryo liver 
culture. Thus the stimulation of erythropoiesis by erythropoie,tin would appear 
to require the initial production of haem, this process being initiated at the 
level of ALA synthetase by erythropdetin. The progress in this work to date is 
reviewed by Gordon (1970).
Woods & Dixon (1969; 1970) have shown that in the perinatal period
the normal activity of rabbit ALA.8 was 4-8 times greater than that of the adult 
animal. Song et al, (1968) found that newborn rats are refractory to induction 
of ALA synthetase by DDC and AIA. This was confirmed by Woods & Dixon in 
rabbits. These facts are of consequence in the problems of haem metabolism in 
the neonate where physiological jaundice and the inability to metabolise various 
drugs may be associated with an inability to regulate the activity of ALA 
synthetase.
Of metals other than iron^only the heavy metals would appear to 
affect porphyrinogenesis. Lead is well known to inhibit ALA.8  (Morrow et al,
1969) and arsenic in the same grouping will do the same (Schwartz & Zagaria, 1951). 
Rubino (1961) found that the inhibiting concentration of lead in vivo corresponds 
to an ’in vitro' concentration of 10*^ - 10~® M leading to an inhibition of 
12 - 22%.
Much of the work carried out on control of haem biosynthesis has been 
carried out on micro-organisms. Indeed the general concept of induction and 
repression (Jacob & Monod, 1961) has only been demonstrated in bacteria.
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Lascelles (1959) showed that under conditions of low aeration 
Bacteriochlorophyll synthesis in R. spheroides begins after a short lag and 
this is preaeeded by a rapid rise in ALA synthetase activity. It was then 
shown that when these cultures were aerated this bacteriochlorophyll synthesis 
and ALA synthetase activity fell rapidly (Lascelles, I960; Higuchi et al,
1965; Higuchi et al, 1968). Lascelles (1968) considers that this is in 
fact a repression by high aeration and further that haem also acts as a 
regulatory factor. In addition ALA acts as an inhibitor although this may 
be due to its conversion into haem. Marriot (1968) and Marriot et al (1968) 
suggested that in R. spheroides this decrease in ALA.S is caused by a 
decrease in a low molecular weight activator and increase in a low molecular 
weight inhibitor, to account for the gross changes in ALA.S.
This inhibition is reversible and Tuboi et al (1969) showed that 
this inhibitor was labile and not identical with haem . One problem at 
this stage is that it would appear that in R. spheroides at least, there are 
two different ALA synthetases of similar molecular weight but varying in 
physical properties which means that in this bacterium there are two control 
systems available for the generation of this enzyme (Tuboi et al, 1970 a). 
Finally in S, Aureus, Tien & White (1968 showed that a population of mutants 
for the production of protoheme fell into five classes, and these five classes 
represented five enzymatic lesions in the haem biosynthetic pathway.
The genes for these lesions were found to be tightly linked and co-transducible 
and arranged in the same sequence as the reactions of the biosynthetic pathway. 
These facts fall in well with the concept of induction starting at ALA 
synthetase and proceeding through the genes to haem synthetase.
In the liver the process of control is postulated to be of a 
similar form, with the genes for this pathway linked in a similar manner.
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Chemical porphyrinogens are thought to derepress the operator gene and lead to 
uncontrolled porphyrin biosynthesis. The only physiological substances yet 
shown to have porphyrinogenic activity are steroids; some of these compounds 
are active in the free or sulphate form but inactive in the glucuronide form 
(Granick & Kappas 1967 a and b). Fhrther,it has been shown that the induction 
was prevented by metalloporphyrins such as haemin; UDP glucuronic acid and 
inhibitors of protein and nucleic acid biosynthesis (Kappas & Granick, 1968). 
Finally, Goldberg et al (1969) have demonstrated that some of these steroids 
are elevated in the urine of porphyric patients in attack and that these steroids 
are porphyrinogenic in rats. On the basis of this work a proposed model of 
control in porphyrin biosynthesis is shown overleaf (Fig.5). ALA synthetase 
production is controlled by an aporepressor and a co-repressor, haem. Haem 
combines with the aporepressor to form firstly the active repressor which acts 
on the operator gene, repressing the biosynthetic pathway which in the final 
analysis stops producing haem. If drugs or chemicals or endogenous compounds 
such as the steroids, displace this haem from the repressor or by other means 
stop production of aporepressor or block the operator gene,the whole pathway 
is derepressed and there is an uncontrolled production of porphyrins. The 
endogenous steroids may be inactivated by glucuronide formation; the other 
compounds are either oxidised by systems such as cyt P450 or detoxified by 
glucuronide formation and rendered inactive. Thus it is likely that in the 
liver porphyrin synthesis is controlled by induction and repression. In the
absence of an inducer the activity of ALA synthetase falls rapidly due to its
very short half life since it has never been shown that ALA synthetase can
be activated or that changed conditions can alter its half life (Stein et al,
1970).
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Pig. 5. Possible scheme of control of the Haem biosynthetic 
pathway. OP - Operator gene: G1 -y G7 : -
Structural genes: E 2 enzymes of the pathway:
UDPGA - Uridine diphosphoglucuronic acid.
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ALA DEHYDRASE
The second enzyme of the haem biosynthetic pathway catalyses the 
condensation of two molecules of ALA to form the monopyrrole Porphobilinogen 
(PBG). Although two bonds are formed, this requires only one enzyme, ALA 
dehydrase ( 5 aminolaevulinate hydrolyase, EC 4,2,1,24) (Granick & Mauzerall 
1958). Bogorad (1960) has summarised the properties of several purified 
preparations of this enzyme. Unlike ALA.S this enzyme is firstly detectable 
in quantity in many animal, plant and bacterial cells, at a very much higher 
specific activity than ALA.S. It is secondly a cytoplasmic enzyme which 
means that in eucaryotic cells, ALA produced within the mitochondrion by ALA.S 
must pass out of the mitechondrion before it can be used by ALA.D for PBG 
production. Finally Doyle and Schimke (1969) showed that the half life of 
the mouse enzyme is 5-6 days as opposed to the l hour of ALA.S. They further 
showed that the perinatal development of the enzyme, proceeds from a high 
specific activity just before birth (about twice adult level) decreases rapidly 
after birth and then rises slowly to adult levels after about 3 weeks.
The enzyme has been purified from many sources; from ox liver 
(Gibson et al, 1959); cow liver (Batlle et al, 1967); human erythrocytes 
(Callissano et al, 1966); yeast (De Barriero, 1968); Soy-bean callus tissue 
(Tigier et al, 1968); wheat leaves (Nandi & Waygood, 1967); R. spheroides 
(Burnham & Lascelles 1963; Nandi et al, 1968) and tobacco leaves (Shetty 
& Miller, 1969).
In some cases the preparation thus produced is electrophoretically 
homogeneous. ALA dehydrase is a sulphydryl enzyme in which activity can only 
be demonstrated in the presence of thiol compounds and requires highly 
reducing conditions for activity.
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Although these factors are common in general for ALA.D,the effect of 
EDTA and various cations varies with the enzyme source. Coleman (1966) noted
activation by EDTA in mouse preparations, yet in most other preparations EDTA
inhibits enzyme activity (Gibson et al, 1955). Nandi & Waygood (1967) reported 
that the inhibition was reversed by and Pe was reported to activate the
mouse enzyme liver (Coleman, 1966), yet to inhibit in oxliver (Gibson et al, 1955) 
and in tobacco leaves (Shetty & Miller, 1969). In wheat leaves the enzyme was 
unaffected by Fe^* and activated by Mn^"^ and Mg^*^ over a wide range of 
concentrations (Nandi & Waygood, 1967), yet in Rhodopseudomonas.spheroides Mn2+ 
activated only at low concentrations and inhibited at higher concentrations 
(Nandi et al, 1968). In addition the enzyme from R. spheroides requires K 
for activation (Burnham & Lascelles, 1963; Nandi et al, 1968).
An activator of ALA.D is reduced glut athione (Nandi et al, 1968) and 
most assays of ALA.D use some reduced sulphydryl compound (De Barriero, 1969).
In these experiments reduced glut-athione (GSH) is used. In Rhodopseudomonas 
spheroides Nandi & Shemin (1968) showed the enzyme to have the properties of an 
allosteric enzyme (Monod et al, 1965) with an equilibrium mixture of three species, 
a monomer, dimer and trimer in the presence of Rb"*" or NĤ '*' ions^ In the absence 
of these only monomer is present. The partially purified ox liver enzyme has been 
found to be highly specific with respect to substrate,neither higher nor lower 
homologues of ALA acting as substrate (Gibson et al, 1955).
The formation of porphobilinogen from two molecules of ALA is essentially
a Knorr readion which involves firstly an aldol condensation,an elimination of water 
from the carbon atom jB to the carbonyl group and the adjacent carbon atom, and the 
formation of a Schiff base between the carbonyl group of one molecule and the 
amino group of the other with the elimination of another molecule of water. Since 
this reaction is catalysed by one enzyme the mechanism of the synthesis must take
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account of the sequence of these reactions. Shemin (1968) and Nandi & Shemin (1968) 
suggested the sequence shown overleaf (fig.6 ) using the formation of heterologous 
pyrroles to prove the sequence. Tlie sequence then is that one molecule of ALA 
forms a Schiff base with the enzyme. This is followed by a nucleophilic attack 
by the enzyme - ALA anion on the carbonyl of a second ALA molecule. This aldol 
eliminates water and the free amino group of the 2nd molecule displaces the 
amino group of the enzyme by transamination or transaldimination to form 
porphobilinogen.
In animals several factors are known to affect ALA.D activity. Of 
these lead is the best known inhibitor of activity (Dresel & Falk, 1956 a and b; 
Lichtman & Feldman, 1963; Gibson & Goldberg, 1970; Morrow et al, 1970). The 
finding that the enzyme activity is depressed in erythrocytes by lead provides 
a sensitive index of lead poisoning in humans (Hernberg & Nikkanen, 1970;
De Bruin, 1968; Bonsignore, 1966; Nakao et al, 1968). Although it has been 
reported that GSH will reverse the depression of ALA.D by lead (Lichtman &
Feldman 1963; De Barriero, 1969),Gibson & Goldberg (1970) found that it was only 
partially reversed and suggested that it had another inhibitory role.
Other factors implicated in affecting of ALA dehydrase are monoamine
oxidase inhibitors. Meo et al (1965) showed an increase in PBG in rat tissues
and in man subsequently to an increase in the blood and urine content of amino
/
ketones and PBG (Bonzanio & Meo, 1965). Iproniazid leads to an increased in
I
vitro synthesis of PBG in rat liver (Rubino, 1965) and similarly to an increase of 
blood and urine levels of aminoketones and PBG and the same results were found with 
Nialamide [(1, (2 benzcarbonyl) ethyl) 2 iso nicotinyl (hydrazine)] (Pisani et al 
1968. They explain the mechanism of action by suggesting that inhibition of 
monoamine oxidase and therefore of ALA oxidase (Pisani et al, 1968) which as a 
step of the Shemin cycle oxidatively deaminates ALA to 2 keto glutaraldehyde, 
leads to a rerouting of this ALA through ALA.D to PBG. A more likely explanation
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is however that these compounds are acting in this manner similarly to EDTA, 
by virtue of their chelating ability and thus reducing enzyme activity.
In humans certain forms of anaemia appear to affect ALA dehydrase 
in the blood. Battistini et al (1970) described an elevated level of ALA 
dehydrase in macrocytic anaemias both in vitamin B12 and folic acid deficiency, 
although there was no significant difference from normal in iron deficiency 
anaemia or in the anaemias of rheumatoid arthritis and carcinomatosis. In 
another form of cancer, Leukemia, Takaku et al (1968) found depressed levels of 
PBG production in the leucocytes in acute and chronic myelogenous leukemia 
this being associated with elevated ALA.S and depressed haem synthetase.
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ANTIBIOTICS
In much of the work carried out on animals in these studies it was 
important to determine whether or not the elevation of enzyme activity by some
substance was an induction or was due to activation or decreased breakdown of the
enzyme. Induction, by definition, is the 'de novo' synthesis of enzyme protein. 
To determine whether or not there was synthesis of protein, it was decided to use 
the antibiotics Actinomycin D and cycloheximide, inhibitors of nucleic acid and 
protein synthesis respectively (fig.7.)
The ability of Actinomycin D to bind to the DNA molecule has long 
been recognised,and it is on the basis of this that it has its inhibitory effect 
on the DNA dependent synthesis of RNA (Reich & Goldberg, 1964),blocking the use 
of DNA as a template for RNA polymerase. Further, at higher concentrations it 
inhibits DNA polymerase. It has a toxic effect on the cell, which may be 
determined by the degree of binding to DNA. In this context there may be some 
similarity between the effects of ionising radiation and Actinomycin D (Elkind, 
1967; Elkind, 1968). The studies of Bachetti and Whitmore (1969) suggest that 
Actinomycin D is a potent cytostatic and cytotoxic reagent which is a potent 
inhibitor of RNA synthesis but which inhibits at concentrations which have an 
effect on DNA synthesis and cell viability. At lower concentrations Actinomycin 
D acts as an activator (Schwochau & Hadwiger 1968; De Matteis 1968; Rosen et al
1964). The action in this way may cause derepression of the gene by combination
of the Act.D. with the regulator gene leading to a derepression of the 
structural gene (Pollock, 1963). On the basis of their data,Schwochau &
Hadwiger (1969) proposed that the mode of activation was by preferential reaction 
with the guanine moiety of double stranded DNA changing the base configuration 
over at least 6 base pairs and resulting in an improper attachment of the 
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Cycloheximide (Actidone; 2 hydroxy 2 - [ 2 oxo 3 . 5 dimethyl cyclohexylj ethyl 
glutarimide) is an antibiotic, extracted from Streptomyces griseus (Sisler- 
Siegel 1967) which inhibits protein synthesis in yeasts (Kerridge, 1958; Siegel 
& Sisler 1964, 1965; Widuczynski & Stoppani, 1965) and higher organisms, rabbits 
(Young et al, 1963) mice (Trakatellis et al, 1965) rats (Gorski & Axinan, 1964; 
Tornheim et al 1969; Yeh & Shils, 1969) and in mammalian cell culture (Bennet et 
at, 1964) yet it does not affect bacterial protein synthesis (Fukumara, 1965). The 
mechanism of action of this compound involves the processes of protein synthesis 
at more than one point. It does not affect the charging of
transfer RNA with amino acids (Ennis & Lubin, 1964) but in fact acts on two of the
sites of a postulated 3 sites on the ribosome. (Culp et al, 1969). The sites
acted on are the donor and acceptor sites. Cycloheximide inhibits the movement 
of peptidyl t. RNA from the arainoacyl (donor) to the peptidyl (acceptor) sites on
the ribosome. (Baliga et al, 1969; McKeehan & Hardesty, 1969).
Baliga et al (1969) in their studies on rat liver have also shown an 
inhibition of polysome aggregation at the initiation of protein biosynthesis and 
a reduction of inactivation by GSH suggesting the inactivation of the enzyme 
involved at this stage,aminoacyl transferase II. Tornheim et al (1969) also 
found that in addition to causing a 69% inhibition of protein synthesis in rat 
liver with a slight inhibition of RNA synthesis, there was a two fold increase in 
DNA, Phosphorus. However this occurred as a gentle rise as opposed to the 
abrupt cessation of protein synthesis and in consequence suggested a separate effect 
of cycloheximide. Since cycloheximide is often used to determine the rate of 
protein turnover it has been suggested that its effect might be due to change in 
the rate of protein degradation. The work of Feldman & Yagil (1969) showed that 
in the presence of cycloheximide, there is no change in the rate of protein turnover 
in cell culture. Further this inhibitory effect is reversible after 12 hours at a 
dosage of l yig/g. body weight which causes an initial 9 5% inhibition of protein
- 24 -
synthesis. Similarly in a study of quantitative aspects Yeh & Shils (1969) 
have shown that at a dosage of 0 . 5 mg/kg the level of protein synthesis is 
minimal for about 3 hours, rising to normal levels after about 16 hours. In 
view of the results from this paper cycloheximide has been used at a dosage of 
Irag/kg to inhibit protein synthesis in the following studies. Since larger 
dosage of this drug leads to secondary changes in organ function such as renal 
change, Fi^ 7 shows the structure of the two antibiotics used in these 
experiments. Their mode of action as explained previously is shown in the 













Pig. 8. Sites of action of Actinomycin D and Cycloheximide 
on the protein biosynthetic chain.
MATERIALS and METHODS
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1) MATERIALS
Allylisopropyl acetaraide was kindly donated by Roche, Welwyn Garden 
City, and ClBA laboratories Limited, Horsham, Sussex, donated Metopirone as 
its ditartrate salt. Actinomycin D, as 'Lyovac Cosmogen’ and 
Dexamethasone as ’Decadron' its sodium phosphate salt were supplied by 
Merck, Sharp & Dohme, Hoddesdon, Hertfordshire. Coenzyme A, Acetyl Coenzyme 
A, Cycloheximide, Pyridoxal Phosphate and UDP Glucuronic Acid were supplied 
by the Sigma Chemical Company, St. Louis, Missouri. Vitamin E was used as 
DLottocopherol acetate as supplied by British Drug Houses, Poole, England. 
Ethanol was used as Burroughs 95% ethanol diluted with distilled water. All 
steroids except DHA sulphate were supplied by Koch Light Limited, Colnbrook, 
Buckinghamshire. KiA sulphate was kindly donated by Dr. J.K. Grant of the 
department of Steroid Biochemistry, Royal Infirmary, Glasgow. The 
barbiturates used were supplied by the pharmacy, Western Infirmary, Glasgow, 
as were glutethimide, as 'Doriden' (CIBA); and Pentazocine as 'Fortral'.
All other reagents were supplied by BDH.
METHODS ■ -
Before commencing these experiments various means of assaying 
ALA synthetase were examined. The difficulty that previous workers experienced 
in the measurement of enzyme activity in non porphyric tissue may be explained by 
their difficulty in producing an enzyme preparation sufficiently quickly, since, 
due to its very short half life, the enzyme activity would have decayed to such 
an extent in any delay,as to make the activity unmeasurable. This failing is 
specific mainly to such assays that use mitochondrial preparations as the 
enzyme source; these assays also have the failing that some provision must be 
made for the production of one of the substrates, succinyl CoA. For these 
reasons it was decided to use a whole homogenate assay for ALA synthetase as 
described by Marver et al (1966).
ALA synthetase was assayed in rat and human liver by measurement 
of ALA production from glycine and endogenously produced succinyl CoA. Iron 
free glassware was used in both assays and was produced by soaking all glassware 
overnight in 'Cristaclean' (Hawksley) and washing in distilled deionised water. 
For rat tissues, the animals were killed by decapitation or cervical dislocation
and the tissues rapidly excised and chilled in ice cold saline.
In the micromethod (Assay 1) the livers were then weighed and a 
weighed aliquot removed for enzyme assay. A 1 in 4 homogenate of liver was then
made in 0.15M tris buffer pH 7.2 containing 0.02 M EDTA; , using a piston
homogeniser (Tri R). An aliquot, 100 >il of this homogenate was then incubated 
anaerobically in the dark with 2 0 pmoles glycine and 10 jiraoles sodium citrate at 
pH 7,4 in a final volume of 200 pi for 1 hour at 3 7 °C. One tube had 200 pi 0.3M 
TCA added immediately to stop the reaction and thus to measure endogenous ALA*, in 
the other tubes the reaction was stopped similarly after the i hour incubation.
The tubes were then allowed to stand in ice after thorough mixing for 
fifteen minutes; then spun at 2 , 0 0 0  g. for 5 minutes at 0 ®C and an aliquot 
of 2 0 0 pi of supernatant removed from each tube for assay and put into a 
boiling tube containing 200 pi H2 O 50 pi Sodium acetate (0.6M) and 20 pi 
acetyl acetone. The tubes were stoppered and boiled for exactly 10 minutes, 
cooled and 50 pi water added, and 500 pi of special Ehrlich’s reagent added 
(Ehrlich/Mercuric chloride reagent). The tubes were allowed to stand for 
fifteen minutes to allow colour development and they were then read at 552 mp in . 
micro cells or semi-microcells. The ALA content was measured from a standard 
graph.
In the macro-method (Assay 2), a lobe of liver was taken, weighed 
and homogenised in 3 volumes of ice cold saline (0.9% NaCl) containing 0.5 mM 
EDTA and 10 mM Tris at pH 7.2. 1 ml of this was taken and incubated with 3 ml.
incubation mixture (100 mM Glycine; 50 mM Tris 6mM EDTA) in 25 ml Erlenmeyer 
flasks in a shaking water bath. The reaction was stopped with 2 ml 2 M HCl and 
the flasks stood in ice for 10 minutes. The contents were then transferred to 
centrifuge tubes, spun at 2000 g for 10 minutes, and the supernatant taken, pH 
adjusted to 4-5 and 0.05 ml acetyl acetone added to the mixture. The tubes
were boiled for 10 minutes and then cooled. This solution was then passed
through a Dowex 1 x 8  column (2 cm x 1 cm) which had previously been 
equilibrated with O.IM HC1/4M NaCi. The column absorbed the pyrroles and the 
eluate was discarded and the column washed through again with 0.IM HC1/4M NaCl 
and 10 ml H^O. Aminoacetone pyrrole (2.4 dimethyl 3 acetyl pyrrole) was 
eluted from the column with 0.01 M N H 4 OH in dry n. Butanol. ALA pyrrole
(2 methyl 3 acetyl 3 propionic acid pyrrole) was then eluted with lOM acetic
acid, 1 ml special Ehrlichis reagent was then added, the volume made up to 3 ml 
and read at 553 mp after 15 minutes.
The details of both of these assays are given in.the Appendix.
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two assays. In consequence the results are thought to be interchangeable.
The important factor in both of these assays is that the conditions are 
determined such that one has firstly, maximal production of ALA with minimal 
production of aceto-acetate and little or no conversion of ALA to PEG. Figure 
9 shows that at a concentration of lOniM EDTA there is little production of 
porphobilinogen. This inhibition of ALA dehydrase by EDTA is non-competitive 
and in addition in this system there are no added thiol activators of ALA 
dehydrase. There is a maximal production of ALA at a glycine concentration of 
100 mM (Fig. 10) and the concentration of succinyl CoA and its production in this 
whole homogenate system is non-limiting. For the 1 in 4 homogenate of liver 
ALA production is linear, . (fig. 1 1 ).
ALA dehydrase activity was assayed in erythrocytes and tissues by 
measurement of the porphobilinogen production from 6arainolaevuLic acid. Lead-free 
glassware was used throughout the estimation, since as other authors have shown 
the lead markedly inhibits ALA dehydrase activity 'in vivo!' The effect of 
lead on ALA dehydrase activity 'in vitro' is shown in fig,12. The physiological 
level of lead is in the region of 10"? molar. For the assay 10 ml. of blood 
was withdrawn by venepuncture, transferred to a heparinised tube in ice and 
centrifuged at 1 0 0 0 g. at 4^C for twenty minutes. The plasma and white cell 
layer were discarded and the red cells washed in 0.15 M potassium chloride and 
centrifuged at 1000 g. for ten minutes. 8 ml. of 0.15 M potassium chloride 
was added to 2 ml. of the packed washed cells and 1 ml. of the resulting 
suspension removed for a red cell count. The sample was centrifuged again and 
the potassium chloride carefully removed. 5 . 4 ml. distilled water was added to 
the packed cells and the sample left on ice for twenty minutes to haemolyse.
1.8 ml. 0.6 M potassium chloride was then added to restore isotonicity. For 
tissues the enzyme preparation was obtained from an appropriate tissue 
homogenate in 0.15 M KCl at 4°C.
n MOLES  
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Pig.9. Inhibition of Porphobilinogen production by EDTA. 
Porphobilinogen was assayed as for ALA dehydrase with varying 
concentrations of EDTA added.
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Fig.10. The effect of Glycine Concentration on ALA Synthetase 
activity. ALA.S. was assayed by the standard method 2 using various 
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Pig. 11. The effect of enzyme concentration on the system of
ALA synthetase assay.
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Pig. 12. Effect of Lead on Rat hepatic ALA Dehydrase activity. 
The enzyme was assayed under standard conditions with varying 
amounts of lead acetate added.
Thunberg tubes containing 10"^ moles reduced glutathione and 10“^ 
moles ALA in 2 ml. 0.1 M phosphate buffer (pH 6.8) were preincubated at 
37^C for fifteen minutes to equilibrate temperatures. 1 ml. of 
temperature equilibrated enzyme preparation was then added to the substrate 
and the tube evacuated. Endogenous porphobilinogen was measured by 
immediately stopping the reaction in one tube with 2 ml. 0.3M trichloracetic 
acid. The test sample was incubated with shaking for one hour at ST^C 
and the reaction stopped in the same way. After ten minutes the solution 
was centrifuged at lOOOg. to remove the protein precipitate. 2ml. Ehrlich's 
mercuric chloride reagent (Special Ehrlich's) was added to 2ml. of the 
supernatant solution and centrifuged again to remove potassium perchlorate 
precipitate. The optical density of the resulting supernatant solution was 
then read between 15 and 45 minutes at the Soret band of 553 np. against a 
reagent blank.
The results were calculated from the molar extinction coefficient 
of 6 . 8  X 104 for porphobilinogen and expressed as nanomoles PBG produced per 
1010 RBC per hour, or as nanomoles PBG produced per g. wet weight tissue per 
hour. The conditions for ALA dehydrase activity determinations, in the 
system used, have been shown to be an incubation of the sample at 
physiological temperature of 37°C (fig. 13) at a GSH concentration of 0.33 x 
lO”^  (fig. 14). The optimal pH for the system is 6 . 8  and it has been 
shown that activity increases linearly as the vacuum increases to 760 mm Hg. 
(fig. 15). Porphobilinogen production proceeds linearly up to one and a 
half hours, (fig. 16).
Protein, RNA and DNA were determined on a combined extraction. 
Protein was measured using the technique of Lowry et al (1951) on a 1 in 800 
dilution of liver homogenate. The standard graph was calibrated using 
Bovine serum albumin. The diluted homogenate was then digested in alkali
TEMPERATURE
HEPATIC 
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Pig. 13. The effect of temperature on rat hepatic ALA 
dehydrase activity. The enzyme was assayed under standard 
conditions.
B IO O D  AlA  D ACTIVITY  
n. m o l # * / h f / l O * N # C
7 0 0 -1
6* 0 -
6 0 0 -
5 5 0 -
ADOED GSH c o n c e n t r a t i o n  ( a l O ' ^ )  M
Pig. 14. The effect of added glutathione on rat blood 
ALA dehydrase activity. Each point represents one assay.
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CHANGE in ACTIVITY




Pig. 15. The effect of vacuujn on Rat hepatic ALA dehydrase
activity. Each point represents one assay. Vacuum was
measured on a Bourdon Gauge.
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Pig. 16 The effect of time of incubation on ALA dehydrase
activity. Each point represents one assay.
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for one hour to hydrolyse RNA which was then measured by its extinction at 
260m p. DNA was measured by the method of Ceriotti (1953, 1955) 
calibrated with calf thymus DNA.
Reduced glutathione was measured in blood by the method of Beutler 
et al (1965) and ethanol was measured by gas liquid chromatography.
Porphyrins and porphyrin precursors were measured by the method of Rimington 
(1962).
Results were calculated and expressed as means - standard 
deviation (S.D.), the standard deviation being calculated from the expression 
S.D. = I L ( x _ 5)2/ Z j ( — î) 
V n _  1
Where x is any of the values, x is the mean value and n the nqmber of 
observations.
The significance of results was calculated by Students 't' test 
using the formula
. =  «1 -
Where s is an estimate of the combined standard deviation of both groups 
calculated from
" i +  “2 “  ^
X and X are the means of both groups and n and n the number of observations 




The effects of sex age diet and allylisopropylacetamlde.
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INTRODUCTION
Experimental porphyria in animals and human porphyria have 
historically followed closely on each other chronologically (Goldberg, 1968; 
1970). The drug used principally in this study as a porphyrinogenesis 
reference point is Allylisopropyl acetamide (AIA) (fig.1.1.) (Goldberg, 1953; 
1954). AIA is porphyrinogenic by virtue of its ability to induce ALA 
synthetase and produces an experimental porphyria very like acute intermittent 
porphyria (A.I.P.). The mechanism of this induction is not yet fully 
understood, but certain facts are known about it. It is known that inhibitors 
of nucleic acid and protein biosynthesis abolish its induction of ALA 
synthetase which would suggest that it is in fact an induction and not an 
activation (Granick, 1965; Narisawa & Kikuchi, 1966; Stein et al 1970).
During the AIA induced increase of ALA.S it was found that haemin (Granick, 
1965) and bilirubin lowered the increase and that this depression might have 
been due to an inhibition of messenger RNA synthesis. Further, the level of 
ALA,S activity in normal animals was also lowered, whilst the level of 
succinyl CoA synthetase was unaffected. (Hayashi et al, 1968). This 
accords well with the concept of feedback repression rather than alternative 
pathways as the source of increased porphyrin synthesis. Indeed AIA does not 
appear to affect PBG utilisation or ALA utilisation by the Shemin cycle or for 
single carbon fragment (C^) metabolism, the tricarboxylic acid cycle or
glycolysis in the liver of animals (Tschudy et al, 1962). The actual 
mechanism whereby AIA acts on the system is not clear. Various attempts have 
been made to relate structure to function (Goldberg & Rimington, 1955;
Granick,1966; Scheck et al, 1968) but this does not completely explain the 
mechanism in view of the diverse structures of the various porphyrinogenic 
drugs.
In this section, an attempt has been made to show the normal levels
2.ALLYL 2. ISOPROPYL ACETAMTOE.
(AIA)
CHg =  CH\
\  /C ---  CH/ \NHg CH  CHg/CHg
Fig 1.1. Structure of A.I.A.
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of the various parameters measured in the subsequent sections in rats, and to 
show the sorts of elevations of activity shown by AIA, and finally to report 
another compound which can diminish the elevation of porphyrins and 
precursors in experimental porphyria, produced by A. I.A.
MATERIALS AND METHODS.
AIA was supplied by Roche Limited, Welwyn Garden City, and useA as a 
propylene glycol syrup of concentration 300 mg/ml. It was administered to 
rats intraperitoneally at a dosage of 300 rag/kg unless otherwise stated. Rats
used were male Sprague Dawley weighing about 200-250g. Methods are given 
previously and in the appendix section. Urine and faeces were collected in a 
metabolism cage (fig. 1.2.) and results are expressed as the mean - standard 
deviation.
RESULTS.
The normal rat hepatic levels of ALA synthetase activity and ALA 
dehydrase activity are shown in Table 1.1., and Table 1.2. shows the normal 
levels of urinary excretion of ALA and PBG in rats. Rat sex does not appear 
to have any significant effect on ALA synthetase activity, although females 
have a slightly higher level of activity together with a higher variance 
(Table 1.3.). Opposed to this age does have a factor to play in this work,
since the activity of hepatic ALA.S in neonates is significantly higher than 
that of adult rats (P<0.001), yet the enzyme is very much less inducible in 
the neonates than in the adult rats. AIA raised the adult activity ten-fold 
(P <  0.001) yet did not significantly alter the activity of the enzyme in the 
neonate (Table 1.4.).
RAT METABOLISM CAGE
GRID TOP to CAGE
F OOD HOPPER
WATER BOTTLE
CLEAR PLASTIC BASE of CAGE
HEAVY GRID (Allows Fo*c#s and Urine 
to Pots Through)SLIDE CONTAINING ^  
FINE GRID to CATCH FAECES STAINLESS STEEL FUNNEL 
GLASS W O O L  FILTER
URINE COLLECTION in CYLINDER
Pig. 1.2. RAT METABOLISM CAGE
This cage Is designed to collect Urine and faeces with 
minimal contamination from food and water.
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LEVELS OF URINARY ALA. & PBG. EXCRETION IN RATS
Treatment No. of Rats ALA. (jug/241ir) PBG. (/Ug/24hr)
Control 40 9.5 + 4.7 4.8 + 3.6
AIA.
(300mg/kg. for 10 102.0 + 10.9 106 + 15.4
4 days)
Results are given as means + standard deviation
TABLE 1.3.
THE EFFECT OF SEX ON HEPATIC ALA SYNTHETASE ACTIVITY IN ADULT RATS (250g)
SEX No. of RATS ALA HEPATIC SYNTHETASE ACTIVITY
(pg/g/hr)
Male 6 6.84 ± 1.45
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The dietary state of the rats is also important since the level of 
ALA synthetase activity in starved rats is significantly greater (P c 0.05) 
than that of rats in a normal nutritional state (Table 1.5.) The effects of 
AIA on this system are summarised in Table 1.6. AIA significantly elevates 
both hepatic ALA synthetase activity and ALA dehydrase activity (P <  0.001) 
and also ALA (P < 0.01) and PBG (P < 0.05) Uroporphyrin coproporphyrin and 
protoporphyrin (P c 0.001).
Vitamin EO^tocopherol) (fig.1.3.) was administered both to normal 
animals and AIA treated animals and was found to significantly depress ALA and 
PBG excretion in the AIA treated animals (P< 0.001) bringing these levels back 
to the base line control level. On its own Vitamin E had no significant effect 
on the normal levels of excretion or on the levels of the hepatic enzymes in 
both normal and AIA treated rats (Table 1.7).
The abolition of the elevation of ALA.8 activity by AIA when these 
rats were treated with antibiotics (Table 1,8) indicates that this elevation was 
due to 'de novo' protein synthesis.
DISCUSSION.
It can be seen from these results that several endogenous factors 
are involved in the control of ALA synthetase activity; the effects of diet 
on porphyrinogenesis are already well documented both in experimental animals 
(Dent & Rimington, 1947; Tschudy et al, 1964) and in humans (Delena & Brown, 
1969; Loriaux et al, 1969; Perlroth et al, 1968; Welland et al, 1964). 
These results confirm that ALA synthetase is elevated in animals starved for 
24 hours. It is difficult to relate this dietary effect to porphyria and 
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to catabolite repression (Magasanik, 1961) by glucose metabolites, but in view 
of the fact that it is impossible to produce compounds within the biosynthetic 
pathway without passing through the agency of ALA synthetase, the initial and 
rate limiting enzyme,this is unlikely.
Although sex differences play some part in human porphyria 
(Goldberg & Rimington, 1962) it does not significantly alter the level of ALA 
synthetase activity in rats. There is however, an age difference. Woods 
& Dixon (1969; 1970) have already demonstrated that there is a perinatal
variation in ALA synthetase activity; these results confirm this in the 
neonatal rat. This high activity in the newborn rat, coupled with the lack
of ability of the enzyme to be induced, suggests that at birth this system is in
a highly 'derepressed' state with a consequent high activity and inability to 
be derepressed further.
In AIA induced porphyria the primary defect is an increase in the 
activity of ALA synthetase by 'de novo' synthesis of enzyme protein (Granick, 
1965). Other defects are induced by this compound such as increases in the 
synthesis of L ascorbic acid (De Matteis, 1964) and a loss of cytochrome P. 450 
and haem. In this work it has been shown that there is an approximately 
tenfold increase in ALA synthetase activity by AIA. This increase in 
activity is unaffected by vitamin E (fig.1.3.) although it lowers the levels of 
excreted porphyrin precursors and porphyrins induced by AIA (Murty & Nair,.1969). 
In this it is possible that its action is due to its role as an antioxidant, 
possibly acting in a manner similar to p carotene in the alleviation of 
porphyrin photosensitivity (Mathews-Roth et al, 1970). Although AIA induces 
a ninefold increase in ALA synthetase activity (as can be seen from the molar
figures (Table 1.9-; as derived from Table 1.6) there is more than sufficient
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In consequence it is not surprising that the activity of the ALA dehydrase is only 
marginally raised whilst that of ALA synthetase is elevated to such high levels.
In total, as can be seen from fig.1.4.,the balance of production of 
ALA in rats against its excretion shows that in the normal state, this pathway 
is operating very efficiently with little excretion of the metabolites on the 
pathway to haem, and thus showing that the tightly linked pathway is efficiently 
controlled at the level of ALA synthetase. When this balance is upset there is 




















CYANURIC ACID AND OTHER DRUGS.
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Soon after the introduction of barbiturates at the beginning of this 
century, they were associated with the onset of acute attacks of porphyria. 
Waldenstrom (1937) put forward the theory that they could precipitate latent 
porphyria into the active form. Since then it has been shown conclusively 
that barbiturates adversely affect acute intermittent porphyria either by 
provoking attacks or, if taken after the beginning of an attack,by 
profoundly aggravating the severity of the neurological symptoms. (Goldberg 
1959). %hen barbiturates were administered to rabbits, it was found that 
out of nine barbiturates, three,each possessing one or two allyl groups 
caused a marked increase in urinary coproporphyrin excretion whilst the 
remaining six caused a slight or no increase in porphyrin excretion although 
all of these drugs have been associated with exacerbation of the human 
disease. (Goldberg 1955).
As has already been shown, a constant finding In experimental
porphyria is an elevation of ALA.S.:for this reason, it seemed profitable to
examine the effects of these same nine barbiturates on ALA.S. activity 
particularly noting the effect of these barbiturates that had failed to cause 
any increase in poiphyrin excretion. With a view to correlating structure
and function, it was also decided to examine the effects of the related
compounds cyanuric acid and glutethimide together with pentctzocine, an 
analgesic containing an allyl group. The subsequent enzyme ALA.D. is also 
thought to be rate limiting in some systems of porphyrin biosynthesis 
(Nandi & Shemin 1967) and also exhibits some characteristics of an allosteric 
enzyme suggestive of a regulatory role (Nandi et al. 1968). For these
reasons ALA D was also measured in these experiments.
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MATERIALS AND METHODS.
The experimental animals were male Sprague Dawley rats, weighing 
about 200g. at the commencement of the experiments. These were used in groups 
of 12, 6 test and 6 control animals,and fed on standard rat diet 41. Drugs 
were administered intraperitoneally as an aqueous solution or orally as a 
propylene glycol syrup. Livers were excised under ether anaeethetic, 
immediately chilled in ice cold saline, weighed, and aliquots removed for 
enzyme and porphyrin assays. The animals were killed by exsanguination before 
consciousness. Liver weights are expressed as g wet weight.
Table 2.1 lists the drugs used, the method and level of dosage. 
Hereafter they will be named by their approved name. These drugs were 




The time course of barbiturate stimulation of A.L.A. synthetase 
activity was studied in detail with phenobarbitone which was administered (at 
anaesthetic dosage) every 24 hours for 12 days. The activity of hepatic 
A.L.A. synthetase rose rapidly to a peak at about 70 hours plateauing about 
200 hours (fig.2.1.) From these results it was decided to administer the 
drugs for six days. The levels of A.L.A. synthetase activity following 
phenobarbitone administration by the two different methods of drug 
administration were not significantly different (Table 2.2). The parameters 
measured on each liver were A.L.A. synthetase, A.L.A. dehydrase, 
coproporphyrin and protoporphyrin (Table 2.3.) Also measured were body weight 
and liver weight. There was no significant difference in body weight change 
or liver weight per 100 g. body weight in any of the groups.
The following were significantly elevated; hepatic A.L.A. synthetase 
activity in all samples, with levels of significance, for Thiopentone 
(P<0.02), for Amylobarbitone (P<0.01) and for the rest (Pc 0.001); hepatic 
A.L.A. dehydrase activity in Dial with a level of significance (P<0.05); 
hepatic coproporphyrin in Dial (P< 0.001) and in Allobarbitone and 
Quinalbarbitone (P<0.01).
No other parameters were significantly elevated. On the basis of the 
results these barbiturates may be separated into four significantly different 
groups (Fig.2.2) In the first group (Dial) the hepatic ALA synthetase 
activity was significantly greater than the activity in the second group 
(Allobarbitone and Quinalbarbitone (P< 0.001). The activity in the second
A.l.A.
SYNTHETASE ACTIV ITY
( w g /g /h r )
7 0 -
MEAN CONTROL AC TIV ITYt SD.
0 3 0 0100 200
TIME(hourt)
Pig. 2.1.: Time course; Effect of phenobarbitone on ALA synthetase
activity. Each point represents one rat. Phenobarbitone 
was administered at anaesthetic dosage every 24 hr during 
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Pig.2.2. The effect of certain barbiturates on hepatic ALA synthetase 
activity in the rat. Each block of the histogram represents 
the mean activity. Vertical bars show the standard deviation
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group was greater than the activity in the third group (Phenobarbitone, 
Barbitone, and Pentobarbitone) (P<0.05) and the activity in this third group 
was greater than in the fourth group (Thiopentone, Amylobarbitone and 
Butobarbitone) (P< 0.001) which was greater than the activity in the control 
group (P< 0. 001).
Following dosage with glutethimide, cyanuric acid and pentazocine in a 
similar manner, it was found that all of these significantly elevated ALA 
synthetase activity (P< 0.001). #ilst neither ALA dehydrase activity or 
body or liver weights were significantly altered.
As a measure of the means of elevation of ALA Synthetase, the effects 
of the antibiotics Actinomycin D and cycloheximide were examined in this 
system. It was found that both of these antibiotics abolished the elevation 
of ALA.S. by phenobarbitone, figs.2.3 and Fig,2.4. It was similarly found 
that these antibiotics abolished the stimulating effect of glutethimide.
The urinary excretion of ALA was elevated significantly by phenobarbitone 
(P< 0.001) Cyanuric acid (Pco.Oi) and Glutethimide (P< 0.001) whilst PEG 
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P H E N O B A R B I T O N E  
100 mg / kg
CYCLOHEXIMIDE
Im g /k g
•  RATS in EACH GROUP
Control Phonobarbltono Control Phonoba^bitono 
P<0*001 Cyclohoximldo Cycloheximide
Pig.2.3. The effect of Cycloheximide on hepatic ALA synthetase in









PHENOBARBITONE lOOmg^g ACTINOMYCIN 0 .0  5mg/kg 







The effect of Actinomycin D on hepatic ALA synthetase activity 




This work has shora that of these nine barbiturates tested, all 
significantly elevated the activity of hepatic ALA synthetase in the rat.
There is also an increase in hepatic porphyrins with three of these drugs,
Dial, Allobarbitone and Quinalbarbitone, that is the three which previously 
caused the greatest excretion of urinary porphyrins in rabbits. There was 
also an elevation of ALA dehydrase in the case of Dial.
On the basis of the elevations of ALA synthetase activity, these drugs 
may be classified into four groups.
(1) Dial, causing a large rise of hepatic ALA synthetase activity and a rise
in hepatic ALA dehydrase and of hepatic copro- and protoporphyrin.
(2) Allobarbitone and Quinalbarbitone, which caused a lesser rise of hepatic 
ALA synthetase activity and a small rise of hepatic copro- and 
protoporphyrins i
(3) Barbitone, Pentobarbitone and Phenobarbitone which caused a rise of 
hepatic ALA synthetase activity.
(4) Thiopentone, Amylobarbitone and Butobarbitone which caused a smaller but 
significant rise of hepatic ALA synthetase activity.
It is noteworthy that this classification is the same as that previously 
based on urinary coproporphyrin excretion (Goldberg, 1954).. fig. 2.5. The main
difference is that in group 4 there was no elevation of urinary
coproporphyrin excretion in the previous study, whilst in the present study, 
the level of ALA synthetase is significantly elevated in all groups including 
group 4. This underlines the rule that all barbiturates are contraindicated 
















■ li I , i , .1 I in.. ■!„ ■„, > I I i I I . IS S § S 8 S S $ S
N !» A H d » 0 < /0 » d 0 0  X7/M7 lYN O W O O V
- 55 -
of hepatic ALA synthetase.
Hepatic ALA dehydrase was also raised in the case of Dial. This enzyme 
is normally found in abundance in all tissues of the body, and is located in 
the cell sap. On the other hand ALA synthetase is mitochondrial in location, 
has a short half life of about 1 hour (Marver, 1966) and is found in very much 
lesser quantities, mainly in the liver and haemopoietic system. It is partially 
by virtue of these characteristics that ALA synthetase is the rate limiting 
enzyme of this pathway. The relative quantities of these enzymes are such, 
that a large rise in ALA synthetase activity does not necessitate a parallel 
rise in the activity of ALA dehydrase, to cope with the increased production of 
ALA. It is consequently not surprising that the levels of ALA dehydrase have 
not been raised.
The hepatic levels of copro- and protoporphyrin were only raised by the 
drugs containing an allyl group, which was also found by Goldberg (1954). •
When the level of porphyrin formation is higher there is clearly some 
accumulation of porphyrins leading to these higher hepatic levels.
The significant elevation of ALA synthetase activity by cyanuric acid, 
glut ethimide and pentazocine is not surprising. Fig. 2. 6 shows the structure 
of the first two of these, and, as can be seen there is a close structural 
relationship between these two compounds, especially gluthethimide and 
phenobarbitone. In this case the inducing ability of these compounds would 
appear to reside in the cyclic lactam grouping associated with all three of 
these compounds, although there is probably some contribution from the rest of 
the structure since the inducing ability of these groups does not appear to be 
related to the number of groups in the molecule. Pentazocine (Fig. 2.7) is not 
structurally a surprise either, since in its structure is an allyl group which has
















Fig.2.6 Structures of Cyanuric acid, Glutethimide and 
Phenobarbitone.






Fig. 2.7. Structure of Pentazocine.
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already been shown to be associated with porphyria in the allyl barbiturates 
and AIA.. Pentazocine is an analgesic with properties similar to morphine 
and other opium dervatives (Laroche and Remy 1970; Jasinski et.al. 1970) 
and in view of these results must be included in the list of drugs 
contraindicated in porphyria (Appendix).
The biochemical relationship between acute porphyria and its sensitivity 
to barbiturates has in the past been ascribed to blocks in the pathway of 
purine biosynthesis (Labbe, Talman & Aldrich 1954) or to impairment of 
acetycholine synthesis by restriction of acetyl CoA through a deficiency of 
ATP limiting its synthesis (De Matteis and Riraington, 1962). The latter 
hypothesis was strengthened by the work of Kyogoku, Lord and Rich (1968) who 
showed that barbiturates form highly specific hydrogen bonded adenine 
derivatives, and suggested that this strong complex is an explanation of the 
physiological activity of barbiturates.
It is now known that in hepatic porphyrias there is an overproduction of 
the initial and rate limiting enzyme of porphyrin biosynthesis, A.L.A. 
synthetase. It has further been shown that the biochemical disturbance of 
human porphyria is associated with the overproduction of hepatic A.L.A. 
synthetase (Tschudy et.al, 1965; Nakao et. al, 1966; Dowdle et. al, 1967). 
Thus the possible mechanisms of drug action in haera biosynthesis are three 
in number;
1) By control of production of Succinyl CoA
The importance of this mechanism is not clear; it must however have 
some part in control of haem biosynthesis since the experiments of Ludwig et.&l. 
(iSGS), have shown that malonate, an inhibitor of succinate dehydrogenase, 
increases porphyrin production 10 fold in the rat.
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2) End product inhibition
Is a much more clearly established method of control in this system. 
Marriot (1968) showed that in Rhodopseudointnas spheroides a decrease in A.L.A. 
synthetase activity is caused by increase of a low molecular weight inhibitor, 
and a decrease of a low molecular weight activator and suggested that a 
reversal of this mechanism might account for activation of the enzyme. This 
method works by change of enzyme activity directly, possibly by alteration of 
the enzyme’s spatial conformation.
3) End product repression
Which involves repression of the de novo synthesis of A.L.A. synthetase. 
This is more indirect in its action involving the apparatus for protein 
synthesisf. Barbiturates could involve any of these 3 mechanisms in order to 
increase the activity of hepatic A.L.A. synthetase. Phenobarbitone induces an 
increase in activity very rapidly within an hour of starting drug 
administration; the increase becomes statistically significant at about 2 hours 
after initiation. This means that the method of action must be a rapid one.
The method of control of this pathway both normally and in drug treated
f ^......................systems is thought to be by de novo induction of enzyme synthesis, as suggested
by the work using nucleic acid and protein synthesis inhibitors. In addition,
phenobarbitone has been shown to increase the microsomal mixed function oxidase,
cythochrome P.450 (Schmidt, Marver and Hammaker, 1966) a haemoprotein central
in hepatic oxidative transformations. As a haemoprotein its increased
synthesis probably relies on the increased function of the haem biosynthetic
pathway. Whether this occurs initially, due to an increase in ALA synthetase
activity by methods such as citric acid cycle control or due to a decrease in the
repressor haem which is being drawn off to produce cytochrome P.450 required to
oxidise these drugs, remains to be elucidated. Thus, although rigorous proof
/ i ^
of de novo induction is not yet available and evidence does suggest that it is
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the main means of regulation, rather than citric acid cycle control, it is 
possible that drug stimulation of this biosynthetic pathway may be through 





Ethanol is known to affect haem and porphyrin metabolism. Some of the 
porphyrias are provoked into attack or episodes of photosensitivity by 
alcoholic excess (Goldberg and Rimington 1962) and the administration of 
ethanol causes a significant elevation of S-aminolaevulic acid (ALA) synthetase 
(Shanley Zail and Joubert 1968; 1969), the initial and rate limiting enzyme 
of haem biosynthesis. There have been no studies up till now on the effect 
of ethanol on ALA dehydrase (S-aminolaevulic hydrolyase^E.C. 4. 2. 1. 24.) 
the second enzyme of the haem biosynthetic pathway which catalyses the 
condensation of two molecules of S-aminolaevulic acid to form 
porphobilinogen (Gibson, Neuberger and Scott, 1955; Schmid and Shemin, 1955; 
Granick and Mauzerall, 1958). This enzyme can now be readily and 
accurately measured in peripheral blood, where it is contained in the 
erythrocytes, and in other tissues. The present study was undertaken to 
examine the effect of ethanol, in man and rats, on blood ALA dehydrase 
activity and to determine whether any changes observed in the blood reflect 




Estimation^ of ALA dehydrase and blood alcohol levels were made in 28 
male patients who attended the casualty departments of the Western Infirmary 
and the Royal Infirmary, Glasgow. Each patient was thought, on clinical 
grounds, to be intoxicated with alcohol and this was confirmed by blood 
alcohol measurement. Their ages ranged from 18 to 68 years. The clinical 
presentation in 14 cases was a head injury but only one patient was 
unconscious from this cause. One patient was admitted to hospital with burns 
to his arms. The remainder had injuries of a trivial nature requiring little 
attention.
Control male subjects, matched for age, were tested at the same time, 
each control having a blood alcohol of nil.
A further investigation was devised to study the effect of alcohol 
during a 24 hour period in normal male volunteers. 2 normal males aged 55 and 
77 were admitted to the metabolic ward of the Western Infirmary. À full 
medical history was taken and a physical examination was performed in each 
case. Haemoglobin, white cell count, serum folate, blood urea, serum 
proteins, liver function tests and serum transaminases were shown to be normal 
at the commencement of the experiment. The 55 year old subject was 
re-admitted after an interval of four weeks and the test was repeated.
Initial blood samples were taken for alcohol and ALA dehydrase levels. The 
subjects were then asked to drink 300 ml. whisky (96 g. absolute alcohol) 
during the course of the first hour of the experiment. Estimations of blood 




Groups of male Sprague Dawley rats weighing between 200 and 250 g.. 
were injected intraperitoneally with 1.5 ml. 50% ethanol^water solution 
eighteen hours and two hours before the termination of the experiments. 
For each group, an equivalent number of control animals were given 1.5 ml, 
dextrose solution of the same caloric value as the ethanol solution, by 
the same route. Blood samples were obtained by direct cardiac puncture 
under ether anaesthesia. Tissue samples were obtained immediately after 
killing the animals by cervical dislocation.
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RESULTS
In studies carried out on intoxicated patients a negative correlation 
(r=-0*86) was found between the blood ethanol concentration and the blood 
ALA dehydrase activity (fig.3,1.) This line has equation y= 374.4 - 0.62x. 
Statistically there was a significant depression (p <  0.001) of blood ALA 
dehydrase activity at a mean alcohol level of 225mg/100ml. Similarly in rats 
administered 1.5 ml. 50% ethanol orally there was a significant depression 
of blood ALA dehydrase activity (p <  0.001) (Table 3,1).
Human volunteers ingested 300 ml. whisky in one hour. When ALA 
dehydrase activity and blood ethanol levels were followed during the 
subsequent 24 hours, as the blood ethanol level was raised so pari-passu was 
the blood ALA dehydrase lowered. Pig.3.2 shows typical results from one of 
these subjects.
Tissue ALA dehydrase activities, measured in rats administered 1.5 ml.
50% ethanol intraperitoneally 2 hours and 18 hours before death (Table 3.2) 
were significantly depressed only in the liver and kidney; the spleen and 
heart enzyme activities were unaffected. At the same time a highly 
significant elevation of ALA S activity was noted, in rat liver(fig. 3.3)
In 'in vitro' studies using human blood haemolysate prepared as for 
the blood enzyme assay, it was found that exogenous GSH reached an optimal 
activating concentration of 3.3 x 10”3 molar followed by a rapid decline in 
activity with increasing GSH concentration. When ethanol at a
concentration of 200mg/100ml was added to the system the optimal activating GSH 
concentration was halved to 1.65 x 10"3 molar and additionally the maximal
level of activation was lowered. This effect was shown additionally by an 
enzyme preparation of rat liver homogenate. (fig.3.4.) In this system 
ALA dehydrase activity fell linearly with rising ethanol concentration with









Figure 3.1: Correlation between blood ethanol and blood ALA dehydrase
activity in humans.
Each point represents the enzyme activity and blood 
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EFFECT OF ETHANOL ON BLOOD ALA. DEHYDRASE 
OF A HUMAN VOLUNTEER
BLOOD










Figure 3.2: Effect of ethanol on blood ALA dehydrase of a human
volunteer.
Dotserepresent enzyme activity, triangles:A Blood 
concentration. These results show effects after ingestion 
of 300 ml. whisky over one hour at the commencement of the 
experiment.
THE EFFECT OF ETHANOL ON RAT HEPATIC ALA SYNTHETASE
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Pig.3.3. Hie effect of ethanol, on rat hepatic ALA synthetase 
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CHANGE IN  A l A D  ACTIVITY  
WITH RESPECT TO M A X IM U M  ACTIVITY
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ADDED GSH CONCENTRATION (x IO '^ M o U i)
Fig.3.4. In vitro effect of variation of added reduced Glutathione
(GSH) concentration with and without added ethanol (ETOH) on 
rat hepatic ALA dehydrase activity. The units of activity are 
nanomoles PBG produced/g. wet wt. tissue/hour.
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coefficient of correlation r = -0.91 and equation y = 701.8 - 0.06 x.
Thus it would appear that this effect is manifested by the depression of 
the optimal exogenous activating thiol group concentration which could be 
explained by an increase in the concentration of endogenous thiol groups.
When rat blood was assayed for free sulphydryl groups it was found that in 
animals treated with ethanol the concentration of blood GSH rose both in 
normal and fasted animals (Table 3.3).
In rats, ethanol is metabolised by the liver at a maximal rate of 10 - 
20mg/100ml/hr. Using a rat liver homogenate system ALA dehydrase was assayed in
the presence of ethanol concentration lOmg/lOOml and in sequence, equimolar 
concentrations of acetaldehyde, acetate and acetyl CoA, the metabolites of 
ethanol. Of these, ethanol produced the maximal depression of activity, 
while acetaldehyde caused about half of this depression and acetate and 
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These results demonstrate a highly significant negative correlation 
between ethanol concentration in blood and tissues und ALA dehydrase activity 
in these tissues. It has also been shown that only in those organs which 
handle the ethanol by metabolism or excretion, the liver and kidney, is the 
activity lowered. The results on AL.A synthetase coOOborate the work of 
Shanley et.al. (1968, 1969). ALA dehydrase has been purified and 
characterised by others in several systems (Gibson, Neuberger and Scott, 1955; 
Nandi, Baker-Cohen and Shemin, 1968; Shetty and Miller, 1969). Nandi and 
Shemin (1968) showed the bacterial enzyme to have the properties of an 
allosteric enzyme (Monod, Wyman and Changeux, 1965) with an equilibrium 
mixture of monomer dimer and trimer activated by potassium ions which are an 
absolute requirement for activity at low substrate concentrations. (Burnham 
and Lascelles, 1963). The enzyme also required thiols for activation. 
Previously, Shanley et.al. (1968) had demonstrated an elevation of ALA 
synthetase, the initial enzyme of the haem biosynthetic pathway, by ethanol. 
This is the rate-controlling enzyme of the pathway (Granick and Urata, 1963) 
and there is evidence for transient porphyrinuria and potentiation of attacks 
of porphyria by ethanol (Goldberg and Rimington, 1962; Holmes and Barnes 
1965). The effects of ethanol on various metabolic systems has been 
studied by others; (Isselbacher and Greenberger 1964: Scheig 1970, Porta
et.al. 1970) it is oxidised through hepatic alcohol dehydrogenase and hepatic 
aldehyde dehydrogenase to acetate and then to Acetyl CoA, microsomal oxidation 
having no effect '’in vivo' (Tephly et.al. 1969). Since the increased 
redox potential (Lindros and Hillbom, 1969) blocks the citric acid cycle 
(Porsander and Himberg, 1969; Williamson et.al. 1969) ethanol is then 
metabolised extra-hepatically to form fatty acids and lipids (Viel, Donoso, 
Salcedo and Varela, 1967). Ethanol also affects many other metabolic
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processes in the liver (Rubin and Lieber, 1968; Lieber and Rubin, 1969).
It is well known that ethanol elevates the redox potential within the cell 
(Zakim, 1968) and Gajdos and Gajdos-Tcirfik (1968) have shown that where ALA 
synthetase is elevated so the NADH level is also raised. Shanley et.al.
(1968) suggested that this elevation of ALA synthetase, a mitochondrial 
enzyme, by ethanol might be due to the altered redox state within the 
mitochondrion leading to a derepression of the ALA synthetase gene by 
substrate induction. This is not unreasonable since Lindros and Hillbom
(1969) have shown that the NADH/NAD*ratio, raised in the cytosol by ethanol 
is paralleled by an equivalent rise within the mitochondrion possibly due to 
increased permeability of the mitochondrion (French 1969). These facts 
presume a subsequent rise in ALA dehydrase activity. That this is not so 
reflects either a secondary control mechanism within the biosynthetic 
pathway or a localised cellular effect possibly due to the changed redox 
potential in the cell.
The limiting step in the metabolism of ethanol is the initial oxidation 
of ethanol to acetaldehyde by alcohol dehydrogenase (Lundsgaard 1938;
Theorell and Chance, 1951; and Westerfield et.al, 1943). Tliis takes place 
in the cytoplasm of liver cells (Nybeig et.al. 1953, Butther 1965). The 
oxidation then rapidly proceeds to Acetyl CoA with the production of two 
reducing equivalents of NADH (Lundquist et.al. 1969) this is shown 
diagrammatically in fig.3.5.
We have demonstrated that ALA dehydrase activity in the presence of 
ethanol needs a lower activating concentration of GSH and that in the absence 
of ethanol, ALA-dehydrase activity falls with increasing GSH concentration. 
Further, of four ethanol metabolites, only one, acetaldehyde, has any 
depressing effect on ALA dehydrase activity and this, like ethanol, is 









































acetaldehyde being independent of the ethanol concentration (Majchrowicz 
and MendeIson 1970). Thus since ethanol utilisation is independent of 
its concentration (Papenberg et.al. 1970) the ethanol effect on ALA 
dehydrase is limited to the initial stages of its oxidation and to the 
production of reducing equivalents. This increased redox potential 
within the cell will upset the balance of the redox state of other 
compounds within the cell. Specifically it may influence the equilibrium 
between the oxidised and reduced forms of sulphydryl compounds. If this 
is so the increased concentration of blood GSH that has been demonstrated 
'in vivo' might inhibit the activity of the enzyme since as we have shown 
'In vitro' the activation of ALA dehydrase by the sulphydryl groups of 
GSi reaches a maximum, after which, ALA dehydrase rapidly loses activity 
with increasing GSH concentration (fig.3.6). Consequently the effects of 
ethanol on ALA dehydrase will be localised to those organs known to 
metabolise or handle ethanol, since it is only in those organs that the 
redox potential will be sufficiently elevated to repress ALA dehydrase 
activity.
Thus we have shown that changes in the activity of a haem enzyme can 
be measured in the blood, and these measurements reflect the enzyme 
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In the past there has been some association of the adrenal gland, 
steroids, and acute intermittent porphyria. Urquhart (1898) suggested that 
adrenal extracts be used in patients with porphyria since diseases of the 
adrenals had been recorded in this condition, and Campbell (1898) gave 
'suprarenal tabloids' to a patient with porphyria without effect. More 
recently, in 1949, Prunty found evidence of adrenal cortical hyperplasia in 3 
patients with porphyria, and Abrahams et al (1947) noted hyperplasia in one 
patient with acute porphyria. Adrenocorticotrophic hormone (ACTH) (Goldberg 
et al 1952) and cortisone (Watson 1954) have been used in the treatment of 
porphyria sometimes,but not normallyywith benefit.
Granick (1966) using a chick embryo liver culture technique 
demonstrated that some steroids had porphyrinogenic activity and in subsequent 
papers (Granick and Kappas 1967 a and b) described more exhaustively the effects 
of a series of steroids. They found that the most potent inducers of porphyrin 
synthesis in chick embryo liver culture were C^g and C21 5 pH steroids, these 
being metabolic products of the steroid hormones. They further showed that in 
the conjugated glucuronide form, these compounds did not induce porphyrin 
synthesis in culture. Kappas & Granick (1967) then showed that this induction 
of synthesis was abolished by Uridine diphosphoglucuronic acid and by inhibitors 
of nucleic acid and protein biosynthesis. In view of these results it was 
suggested that these steroids induced the 'de novo' synthesis of ALA synthetase 
in this system. These steroids were the first natural compounds to be 
implicated in porphyrinogenesis and its control.
Subsequently Levere et al (1967); Kappas et al (1968) and Kappas and 
Granick (1968b) showed that these steroids do induce ALA synthetase in erythroid 
cell culture and chick embryo liver culture, although they were unable to 
demonstrate any enhanced ALA synthetase formation in guineapig or rat liver by 
these steroids. Although these facts indicated that steroid imbalance might be
associated with porphyria. Tsohudy (1968) could find no evidence for elevated
urinary 17 ketosteroids in patients with hereditary hepatic porphyria. In
the following year, however, Goldberg et al (1969) in a study on humans and 
rats, showed elevated fractions of some urinary 17 ketosteroids in the urine 
of patients with acute intermittent porphyria although the total 17 ketosteroid 
levels were within the normal range. It was further found that one of these 
steroids dehydroepiandrosterone (DHA) caused an elevation of ALA synthetase in 
rat liver. Necheles & Rai (1969) then showed that one of the 5 steroids,
etiocholanolone, caused an increase in the uptake of glycine into haem in
human bone marrow cells. This was abolished by actinomycin D and puromycin.
It was then found that plasma from patients in attacks of A,I.P. was capable of 
inducing ALA synthetase in chick embryo liver culture and again nucleic acid and 
protein biosynthesis inhibitors abolished this effect. It was also shown that 
this effect was produced by the plasma of some patients receiving oral 
contraceptive steroids (Kappas et al, 1969). Finally, in mice Gorshein & 
Gardner (1970) showed that these 5 pH steroids stimulated 59Pe incorporation 
into erythrocytes.
As Kappas et al (1969) showed, there is some association of oral 
contraception with porphyria, yet the role of oral contraception, and 
oestrogens in porphyria is difficult to define. In the past there have been 
conflicting reports on the effects of these compounds on A.I.P. and other 
porphyrias. In 1960 Watson described cases of patients treated with oestrogens 
for carcinoma of the breast and prostate who showed photocutaneous 
manifestations of hepatic porphyria. He then found increased PEG and 
uroporphyrin in cases of latent porphyria treated with stilboestrol (Watson 
et al, 1962). Redecker (1963) studied patients with A.I.P. and found increased 
urinary PEG excretion after treatment with oestrogens and progestrogen. There 
has been suggested relationships between A.I.P. and contraceptives (Wetterberg, 
1964), and Koskelo et al (1966) showed elevated urinary ALA after contraceptives
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and similar results were reported for ethinyl oestradiol (Welland et al 1964) 
whilst Becker (1965) described three cases of porphyria cutanea tarda induced 
by stilboestrol.
Despite this, combined contraceptive pieparations have been used to 
alleviate the symptoms of porphyria in some female patients in whom the attacks 
of porphyria could be associated with pregnancy or onset of menses (Welland et 
al 1964; Haeger-Aronsen, 1963; Perlroth et al 1965). Copeman et al (1966) 
on the contrary found no change in porphyrin excretion after oestrogens.
In a study on rats Tschudy et al (1967) found that oestradiol caused 
oscillations in the hepatic levels of ALA synthetase and ALA dehydrase. They 
suggested that this was due to a perturbation in the negative feedback loop 
control of the pathway with any elevation of these enzymes merely being a 
rebound after a decline in activity.
Finally, Rifkind et al (1970) have examined this induction of ALA 
synthetase by these contraceptive steroids, in chick embryo liver culture.
They found that the active component of these steroids was the progestogen . 
whilst no oestrogen significantly altered the level of enzyme on its own.
The normal processes of C ig and C2 1 steroid biosynthesis are shown on 
fig. 4 .7 . In this study the effects of a number of these steroids have 
been examined on an *in vivo’ rat system.
METHODS
The nomenclature used in this section for these steroids is based on 
the numbering system shown for the steroid nucleus in fig. 4.1. In the series 





Fig. 4.1. "Die numbering system of the steroid nucleus and 


























5 a -  oestrane 5 /3 - oestrane
Pig. 4.2 The names and formulae of the Ĉ g, C21 and Ĉ g steroid 
parent compounds ( Me - Methyl; Et - Ethyl)
These double bonds are designated respectively A 4  or 4 and A5 or 5. Figure 
4.2, shows the C1 9 C21 and C1 8 steroids respectively. These are described, 
when fully saturated.according to the conformation of the hydrogen at carbon 5 . 
When it sticks above the ring it is^p^and below the ring^cCgiving bent and planar 
structures respectively (fig. 4.3). In both of the 4 and 5 unsaturated cases 
the rings are bent whilst the fully unsaturated aromatic oestrogen ring is 
again planar. (Pig. 4.3).
During these experiments unless otherwise indicated these steroids 
were administered at a dosage of 1 mg/kg to the rats, as an intraperitoneal 
injection of a concentrated ethanol solution (250 mg/ml) or if insoluble as an 
aqueous suspension of the same strength. Steroids were administered every 24 
hours until the termination of the experiment. In all cases an equivalent 
number of matched control animals were treated and killed at the same time as 
the test animals. The animal experimental plan for the antibiotics 
experiments is shown in fig. 4.4. In this^ the animals were treated for three 
days. The figures refer to the time in hours of the experiment. Cycloheximide 
was administered 4 hours^and actinomycin-Dj7 hours before death to allow 
sufficient time for their effects to take place.
There is a daily rhythm in the metabolism, of metopirone by rats 
(Szeberenyi et al 1969) with a trough in activity at 1 0 .0 0 am and peak at 
10.00 p.m. In our experiments the substance was administered at 10.00 a.m. 
to allow for a lower toxicity of this substance at this time since it has been 
shown to be more toxic in mice in the evening (Ertel et al 1963).













(Im g /k g )
CYCLOHEXIMIDE
( Im g /k g )
ACTINOMYCIN D 
(0 '5 m g /k g )
DEATH




Pig. 4.4. Animal Experimental Plan, Antibiotics experiment. 




Table 4.1, showed the series of steroids studied in these experiments. 
The nomenclature is as explained before and they are numbered to facilitate 
their identification in subsequent tables. These steroids fall into three 
groups according to the number of carbon atoms in their structure, that is
C 2 1 , C 19 and C 1 8 •
Table 4.2 shows the effects of the C 21 steroids. Significant 
elevations (p < 0.001) of hepatic ALA synthetase were found in rats.treated with 
17 hydroxpregnenolone. No other figures were significantly elevated. Table 
4.3 shows the effects of C^g steroids. Of these androstenedione and 
dehydroepiandrosterone significantly elevated ALA synthetase activity (p <  0.001) 
whilst androstenediol and etiocholanolone also elevated ALA.8 activity at a 
lower level of significance, (p <  0.02). None of the Cis steroids elevated the 
activity of ALA.S. (Table 4.4) whilst the activity of ALA dehydrase was 
unaffected by any of these steroids.
2) Studies oii Dehydroepiandrosterone(DHA)
Significant elevations (p ^  0.01) of hepatic ALA.S levels were found 
within 24 hours after a daily intraperitoneal injection of 0.5mg free DHA 
reaching maximal levels at about 72 hours, (fig. 4.5). Injection of DHA 
sulphate also caused a significant elevation of hepatic ALA.S in rats (p <  0.001) 
whilst DHA acetate and DHA with equimolar amounts uridine diphospho-glucuronic 
acid had no significant effect on activity over the control activity (Table 4.5).
This elevation of ALA.S by DHA was followed in/a time course 
experiment and studied using the antibiotics cycloheximide and actinomycin D.




SYSTEMATIC NOMENCLATURE NUMBER COMMON NAME
19
18
4 Pregnen 3.20 Dione 1 Progesterone
5 Pregnen 3 ^ ol 20 One 2 Pregnenolone
5 Pregnen 3 p 17be d i d  20 one 3 17 Hydroxy 
Pregnenolone.
5p Pregnan 3^20<XDiol 4 Pregnandiol
5p Pregnan 3(X 17(X 20oLTriol 5 Pregnantriol
4 Androsten 3, 17 Dione 6 Androstenedione
4 Androsten 17 pol 3 One 7 Testosterone
4 Androsten 3, 11, 17 Trione 8 Androstenetrione
5 Androsten 3 ^ 1  17 One 9 Dehydro Epi 
Androsterone (DHA)
5 Androsten 3 p 11 p Diol 10 Androstene Diol
5^ Androstan 3, 17 Dione 11 Etiocholan Dione
5p Androstan 3 K 0 L  11,17 Dione 12 11 Keto Etio 
Cholanolone
5p Androstan 30C17 p Diol 13 Etiocholandiol
5p Androstan 3oiOL 17 One 14 Etiocholanolone
5 Androstan 3o^OL 17 One 15 Androsterone
5 Androstan 3 17 One 16 Epi Androsterone
5 Androstan 3, 17 Dione 17 Androstan Dione
1,3,5 Oestratrien 3,17 p D i d 18 Oestradiol
1,3,5 Oestratrien 3,16o(, lip Triol 19 Oestriol
1,3,5 Oestratrien 30L 17 One 20 Oestrone
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Fig. 4.5. The effect of daily intraperitoneal injections of 
DHA on hepatic ALA. synthetase activity in rats.
Each point represents one animal, the mean control level is the 
mean hepatic ALA.S. activity in 25 rats.
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The results are shown in figure 4.6. The time course of elevation followed a 
pattern similar to the previous time course experiment (fig.4.5.) Each point 
on the figure represents one animal, the arrows indicate the time of dosage of 
DHA (1 mg/kg); as can be seen both actinomycin D and cycloheximide abolished 
the DHA elevation of ALA.S. activity; indeed they abolished all activity in 
about 8 and 10 hours respectively. All three hepatic porphyrins were 
significantly elevated by DHA (Table 4.6).
3) Steroid antagonists.
In this section the effects of the compounds metopirone, and 
dexamethasone were investigated (fig.4.7). Metopirone significantly elevated 
ALA. S. activity (p< 0.001) and depressed ALA.D activity (p< 0.001) (Table 4.7). 
In animals treated with AIA (300 mg/kg) dexamethasone had no effect on the 
enzyme levels of the rats although in the animals treated with both AIA and 
dexamethasone, there was a large improvement in the condition of the animals 
(Table 4.8 )•
DISCUSSION.
The various pathways of steroid metabolism are shown in fig.4.8. These 
are collated from Lorraine & Bell (1966); Cantarow & Schepartz (1967); Cameron 
et al (1969) and Payne and Mason (1969). Of the steroids shown in this scheme
only those ones marked with an asterisk, that is 17^C hydroxypregnenolone, DHA,
DHA sulphate, androstenedione and etiocholanolone have been shown to have some 
porphyrinogenic activity in the present system. Of these, the most potent 
inducer was DHA, and this was picked out for further study. These results are 
to some extent in agreement with the work of Granick & Kappas (1967) who showed 
that the most potent inducers of porphyrin fluorescence in chick embryo liver
EFFECT of ANTIBIOTICS on DHA STIMULATION of ALA SYNTHETASE
Hepatic 
ALA S Activity 
(p o /g /h r)





20 40 60 .80 100 Hours
Fig. 4.6. The effect of intraperitoneal injections of DHA and 
Actinomycin D and Cycloheximide on the activity of rat hepatic ALA 
Synthetase.
Each point represents one animal. Circles represent animals treated 
with actinomycin D; triangles, cycloheximide.
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culture were the 5 jBH steroids. Their system did not implicate the unsaturated 
steroids to any great extent. This may be due to species differences in the 
metabolism of steroids since it has been shown that there are differences in the 
incorporation of steroids into mammalian and avian erythrocytes (Ohtsuka &
Koide, 1969) which suggested a variation in the species metabolism of these 
compounds which would probably apply to other cells.
The effects of dehydroepiandrosterone (DHA) whose structure is shown 
opposite (Pig. 4,9) were examined in greater detail. It significantly elevates 
ALA synthetase activity as does its sulphate, yet it does not effect ALA 
dehydrase. Both actinomycin D and cycloheximide abolish this elevation of ALA.8 
by DHA and this suggests that the elevation of activity thus produced is due to 
the 'de novo' synthesis of ALA synthetase. It was further found that the 
glucuronide and acetate conjugates of these steroids were ineffective as inducers 
of the enzyme. Again these results are consistent with the work of Kappas & 
Granick (1968). It was also found that hepatic porphyrins are elevated as would 
be expected with a highly elevated ALA synthetase activity.
In previous work on human patients with acute intermittent porphyria 
(Goldberg et al, 1969) it was shown that of the fractionated 17 ketosteroids In 
urine, DHA was one of the most highly elevated steroids in several patients in 
attack. Jones & Griffiths (1968) showed that in the adrenals, DHA sulphate is 
produced in the zona reticularis by its sulphokinase. For this reason it was 
decided to study the effects of dexamethasone^used to suppress adrenal function^ 
on acute intermittent porphyria. Dexamethasone causes a decrease in the urinary 
excretion of DHA and other 17 hydroxycorticosteroids (Lorraine & Bell, 1966).
It was found that in A.I.P. dexamethasone caused a significant reduction in the 
urinary steroids measured, especially DHA and in addition urinary porphyrins and 
precursors were significantly depressed (Moore et al 1969) fig. 4.10. - In 
animal studies there was no change in hepatic enzyme levels or porphyrins during 
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Plg. 4.9. The structure of Dehydroepiandrosterone (DHA)
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Fig. 4.10 The Effect of dexamethasone on the urinary excretion 
of Porphyrins and 17 ketosteroids in a human male suffering from 
Acute Intermittent Porphyria.
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physiological improvement in the animals condition. The lack of change may be 
because in the hypothetical scheme of control AIA does not act through the 
steroids but rather acts on its own against the repressor mechanism. Its effect 
in humans is probably related to suppression of ACTH release (Sirett & Gibbs,
1969) but may also be due to other factors in this system, since it has been 
shown to lead to a significant depression of citric acid levels in humans
(Wajchenberg et al, 1969). This depression of citrate could lead to a
depression of succinate with a subsequent decrease in the entry of succinyl CoA 
substrate into the biosynthetic pathway.
The effect of metopirone (2 methyl, l, 2 bis (3' pyridyl) 1 
propanone) and its assessment is less easy. It is known to inhibit various 
adrenal mitochondrial steroid hydroxylases (Liddle et al, 1958; Sanzari &
Peron, 1966) and since these are similar to drug metabolising enzyme systems in 
the liver mediated by cytochrome P.450 as the terminal oxidase (Estabrook et al 
1963; Omura et al, 1965) it also interferes with drug hydroxylation (Leibman 
1969). In addition Kahl & Netter (1970) have shown that it also inhibits 
respiration of liver slices and leads to a change in the redox state of the cell 
and an increase in aerobic glycolysis. In these experiments it was used with a 
view to blocking the formation of cortisol and corticosterone with a subsequent 
rise in 17 hydroxycorticosteroids induced by elevated ACTH (Lorraine & Bell 1966).
To this end it may be that the elevation of ALA synthetase is related to the rise
in these steroids but in view of the other cellular effects of this compound, it 
would be unwise to ascribe totally this rise to the rise in these steroids. The 
depression of ALA dehydrase activity may be due to the altered redox state of the 
cell (Section 3.)
The case for or against the use of oral contraceptives in porphyria 
is complicated. It seems certain that the progestogen content of 'the pill' 
is porphyrinogenic ahd that the oestrogen content has no effect on the haem
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biosynthetic pathway (Rifkind et al 1970) as would appear to be further corroborated 
by the results found in this study which show oestrogens to be ineffective in 
raising ALA.8 activity, as are synthetic oestrogens like mestranol (Aitken and 
Moore 1970), whilst some androgens and one progestogen are effective. In 
opposition to the hypothesis that DHA is the effective substance in this system, 
Bulbrook & Hayward (1969) have shown that oral contraceptives lower the urinary 
excretion of DHA and of other 17 OH corticosteroids and 11 deoxy 17 oxosteroids.
In women, in general, fluctuations of the urinary total 17 oxosteroids may be 
observed during the menstrual cycle and these steroids increase in amount during 
pregnancy (Lorraine & Bell 1966). Longhino et al (1968) measured the urinary 
excretion of certain of these steroids during the menstrual cycle and showed 
that there was some fluctuation in these levels, with both androstenedione and 
DHA elevated during the luteal phase of the cycle. It is now known that there 
is a sex/age correlation between the Incidence of acute intermittent porphyria 
and urinary 17 oxosteroid excretion. Hamburger (1948) showed that the levels 
of urinary 17 ketosteroid excretion in men reached a peak in the fourth decade 
of life whilst in women it was greatest in the third decade. (Fig. 4.11). The most 
frequent age of onset of symptoms of A.I.P. in males is again in the fourth 
decade of life and in females in the third decade (fig. 4.12) (Goldberg &
Rimington, 1962). Thus there is a direct correlation between these two factors 
in acute porphyria.
URINARY 17 KETOSTEROID EXCRETION in NORMAL HUMANS
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Fig. 4.12. The Age of onset of attacks of porphyria in human 
males and females.
SECTION 5
STUDIES IN HEREDITARY COPROPORPHYRIA
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INTRODUCTION
The history of porphyria» as such, in humans only commenced less than 
one hundred years ago. (Goldberg & Rimington, 1962). There are basically 
two types of porphyria, erthropoietic and hepatic porphyria . Hereditary 
coproporphyria is a hepatic porphyria which is characterised from the other 
hepatic porphyrias by the excessive excretion of coproporphyrin in faeces 
and urine at all times, accompanied by an elevation in porphyrin precursor 
excretion in acute attacks.
There are four commoner forms of hepatic porphyria; acute 
intermittent porphyria; variegate porphyria; porphyria cutanea tarda and 
symptomatic porphyria, of which,the first three are inherited as Mendelian 
aûtosomal dominants and the last is acquired, usually through alcoholic excess. 
There is also the less common hereditary coproporphyria which is also 
inherited as a Mendelian autosomal dominant.
Tschudy et.al (1965) produced the first communication on elevated 
hepatic ALA.Synthetase activity (ALA.8) in porphyria in a patient with Acute 
Intermittent Porphyria (A.I.P.,) who died and from whom tissue was obtained 
shortly after death. The second communication was from Nakao et.al (1966) 
who also reported that ALA.S was elevated in another patient with A.I.P.
The tissue in this case was obtained surgically. Dowdle et.al (1967) 
reported elevated ALA.S. activity in six patients with porphyria, one with 
A.I.P., two with variegate porphyria and 3 with symptomatic porphyria. In 
addition two normal human values were given. In these studies the samples 
were obtained by needle biopsy. In 1966 Levere reported a case of 
stilboestrol-induced hepatic porphyria with elevated ALA.S. activity and in 
addition two normal values. In a larger study on twelve subjects with
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symptomatic porphyria Zail & Joubert (1968) showed that all of the patients 
with porphyria had high levels of ALA synthetase activity. Finally in 1969 
Masuya published a paper dealing with both hepatic and erythropoietic 
porphyrias in which he quoted figures for elevated P A  synthetase activity in 
2 patients with A.I.P., 1 with variegate porphyria and 1 with cutaneous 
porphyria.
There have been many other papers dealing with the metabolism of haem 
in porphyria which have not measured ALA synthetase activity directly but have 
indicated that this enzyme is raised. Dowdle et.al (1968) measured the 
distribution of labelled ALA in patients with porphyria, and concluded that 
the excessive haem precursor production in A.I.P., variegate porphyria and 
symptomatic porphyria cannot be explained by a block in any alternative 
pathways of ALA metabolism. They suggested that in each of these hepatic 
porphyrias the cause was an initial elevation of ALA synthetase activity 
although there would appear to be other defects in both A.I.P. and 
symptomatic porphyria. None of these previous authors quote any work on 
hereditary coproporphyria. This section deals with the activities of hepatic 
ALA synthetase and blood ALA dehydrase in this porphyria both in attack and 
remission, in addition to urinary and faecal porphyrin levels and levels of 
urinary 17 oxosteroids.
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MATERIALS AND METHODS 
Human Studies.
Levels of urinary 17 oxosteroids, uroporphyrin, coproporphyrin PEG, 
ALA were measured in 4 patients with hereditary coproporphyria of whom two 
were in attack (L.L. and A.B.) In addition measurements were made of blood 




In June 1969 A.B., a 30-year old housewife was admitted to hospital 
for hysterectomy and appendectomy. Following surgery she complained of 
persistent lower abdominal pain, anorexia, constipation and symptoms of 
cystitis. She had difficulty in sleeping and became increasingly agitated 
and depressed. She had always been a nervous person and at the age of 21 
years anorexia nervosa had been diagnosed. 3 years later she had become 
depressed and needed in-patient care. Following hysterectomy post operative 
management included treatment with a proprietary mixture of butobarbitone and 
promethazine, papaveretum and several antibiotics. She was discharged on 
July 14, but her mental state became worse and psychiatric advice was sought. 
On July 22 a diagnosis of agitated depression with hysterical features was 
made and the patient admitted for psychiatric care. She was given 
amylobarbitone and imipramine. In spite of this treatment the patient's 
condition deteriorated with the appearance of confusion and paranoia. 
Electro^convulsive therapy was started. The depression improved but periods 
of acute restlessness and confusion occurred frequently. Her gait became
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unsteady and there was a coarse tremor of both arms and legs. Her urine had 
been noted to be dark during her surgical admission but the significance of 
this finding was not appreciated until August 7, when PBG was found in the 
urine and a diagnosis of acute intermittent porphyria made. Therapy with 
barbiturates and other drugs was stopped and treatment with chlorpromazine 
instituted. Abdominal pain, which had been a persistent feature cleared 
within 24 hours but her mental state remained abnormal. She was transferred 
to a general hospital. On physical examination her blood pressure was normal 
but her pulse rate was invariably above 90 per minute. Neurological 
examination revealed no objective weakness, or no sensory disturbance and 
there was no reduction in vital capacity. However her knee jerks became 
progressively more difficultto elicit, although there was no other evidence 
of peripheral neurological disease. Her mental state gradually improved 
and she was discharged at the end of September,
This patient is a member of a large family of whom 2, mother and 
sister, have been found to have a latent form of the disease with elevated 
coproporphyrin in urine and faeces.
This case history is reproduced by kind permission of Dr. McIntyre, 




This patient (L.L.) - a 17 year old girl - was admitted in April.1968 
to a surgical ward in Victoria Hospital, Kirkcaldy. She gave a five day 
history of colicky abdominal pain and diarrhoea. She had been previously 
healthy and there was no family history of disease. On physical examination 
considerable tenderness was noted in the right iliac fossa, and 
appendicectomy was carried out using thiopentone sodium to induce anaesthesia. 
The appendix was of normal appearance. Post-operatively she vomited
considerably and developed a mild pyrexia. Her blood pressure was found to
be 170/100 mm Hg. At this stage it was noted that she was two months 
pregnant. One month post operatively she became slightly icteric with a
bilirubin of 3.8 mg/100 ml. and raised transaminases. Three weeks after the
onset of the icterus she developed a bullous eruption on the light exposed
parts of her body. She was then found to be excreting huge amounts of
coproporphyrin in her urine and faeces. The rash subsided after one week and 
thereafter she remained well until November 1968 when she was delivered of a 
still-born child.
Her second pregnancy was started in March 1969 and this proceeded
uneventfully to term when a normal healthy child was born. One week after
delivery she became acutely ill with abdominal pain and vomiting. Her 
blood pressure rose to 220/130 mm Hg and she suffered several epileptic 
seizures. This episode was accompanied by the urinary excretion of large 
amounts of ALA and PBG. After 10 days she began to improve rapidly and has 
had no symptoms since that time. Porphyrin analysis of her family revealed 
three examples of the disorder in latent form.
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CASE 3.
This patient, J.McS, a 48 year old man, first presented in 1966 with a 
history of nervousness for a number of years. He had been drinking heavily to 
relieve the symptoms. There was no history of abdominal pain, vomiting or 
constipation. His urine had never been dark. On examination no abnormal 
findings were made. When his urine and stool were examined however, they 
showed grossly elevated levels of coproporphyrin. He has been seen regularly 
since then with no change in his clinical state.
CASE 4.
This patient, I.K., a 26 years old housewife, presented in 1966 during 
her second pregnancy with a urinary tract infection. Her Urine was noted to be 
dark after a short course of sulphonamides and was found to contain increased 
amounts of PBG; the only other symptom was depression of 2 years duration. 
Quantitative porphyrin analysis showed large amounts of coproporphyrin in both 
urine and faeces. The pregnancy ended with a neonatal death, the cause of which 
uncertain. Her next presentation in 1968 was with a further attack of 
depression during the early stages of her third pregnancy. This settled quickly 
and she proceeded to give birth to a normal live child. Since that time she has 
remained in remission. There is no evidence for other cases of this disorder in 
other members of her family.
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METHODS:
The analysis of the steroids was carried out in the Department of Steroid 
Biochemistry, Royal Infirmary, Glasgow by J. Paxton, by whose permission I 
reproduce these steroid results. Individual urinary 17 oxosteroids were 
estimated by the method of 0’Kelly (1968) which permits measurement of individual 
17 oxosteroids as the separated steroid glucuronide and sulphate fractions of 
24 hour urine specimens. The steroid conjugates are split, the sulphates by 
solvolysis and the glucuronides by p. glucuronidase. The free steroids are 
extracted, separated into groups by T.L.C. and measured as their trimethyl silyl 
ethers by gas liquid chromatography. Hepatic biopsies were obtained by needle 
biopsy^other methods are as in the methods section.
RESULTS:
Table 5.1 shows the normal levels of porphyrin excretion in urine and 
faeces. These are taken from Goldberg (1966) except for the asterisked values 
which are given by Moore (1970).
The results of the measurement of urinary porphyrins and precursors and 
faecal porphyrins are shown in Table 5.2. For all four of these patients the 
values are markedly elevated above the normal levels, and both patients in 
attack show much higher levels of urinary excretion of these substances than the 
patients in remission. The faecal protoporphyrin values are low. These 
figures are typical of hereditary coproporphyria (Berger & Goldberg, 1955).
At the same time as these collections were made, blood was withdrawn for 
ALA dehydrase assay and, in two of the patients, a needle biopsy sample was 
obtained for ALA synthetase assay. It was found that in these patients, only 
the two in attack showed any elevation of enzyme activity, both showing elevated 
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were normal in remission (Table 5.3)
When the fractionated urinary 17 ketosteroids were measured in these 
patients it was again found that only in the patients in attack were any 
steroid levels elevated, these values being normal in states of remission, 
whilst at the same time it was noted that all of the 24 hour urinary excretions 
of porphyrins and precursors were highly elevated in the patients in attack 
(Table 5.4).
DISCUSSION
The figures in Table 5.2 support the diagnosis of hereditary 
coproporphyria in these patients. The typical presentation of hereditary 
coproporphyria is highly elevated coproporphyrin in stool and urine 
associated with elevated porphyrin precursors in attack. In hereditary 
coproporphyria, the main permanent defect is elevated urinary and faecal 
coproporphyrin excretion in remission as well as in attack; this may be 
associated with a deficiency in coproporphyrinogen oxidase activity. In acute 
attack the extra factor which comes into play is thought to be an elevated 
activity of ALA. synthetase which is associated with raised urinary ALA and 
PBG excretion in addition to an elevated excretion of coproporphyrin.
These results have shown that ALA synthetase is elevated in one 
patient with hereditary coproporphyria in attack, as it is in other hepatic 
porphyrias. This is the first report of elevated ALA.8 in hereditary 
corproporphyria. In the other case measured in these studies the level was 
normal but in this case the patient had always been in remission. In both 
cases in attack erythrocyte ALA dehydrase activity was elevated and in cases
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in remission the activity of this enzyme was normal or low. In the case of 
J.McS, the ALA dehydrase activity was low. This might be attributed to 
alcohol ingestion (Section 3).
In all of these patients the levels of porphyrin excretion are high 
although they are higher in the patients in attack. This elevation of these 
porphyrins can be related to the elevation of some urinary steroid levels in 
these patients in attack. This corresponds to the observation in previous 
work that the levels of certain urinary 17 oxosteroids are elevated in A.I.P., 
this always being the case in patients in attack (Goldberg et al, 1969). It 
is interesting to note that in all of these cases compounds that have been 
investigated previously in this thesis are implicated in the exacerbation of 
this disease in humans. The principal offenders are the barbiturates which
have clearly been shown to be porphyrinogenic, both in this work and from 
previous work. The second offender is ethanol and the last the 
sulphonamides, which were first implicated by Rimington and Hemmings (1939) 
and more recently shown to raise hepatic ALA synthetase activity in rats 
(Beattie et al, 1970). Thus the elevation of hepatic haem enzyme levels and 
urinary porphyrins, precursors and steroid levels in hereditary copro-porphyria 
can be related to the clinical severity of the disease. These results lend 
strong support to the hypothesis that in hepatic porphyrias in attack, the 
accumulation of haem precursors is due primarily to the excessive activity 
of the initial and rate limiting enzyme of haem biosynthesis^ALA synthetase.
GENERAL DISCUSSION
In these experiments the effects of various compounds on the ability of 
rat liver to synthesise 6aminolaevulic acid and hence Haem have been examined.
This ability to synthesise haem is a biochemical function common to all aerobic 
cells, bactenal, plant and animal, since as well as being the pnx&hetic group of 
haemoglobin, haem is also required in various cytochromes, catalases, peroxidases 
and other haemoproteins as well as being used in the magnesium rather than iron 
porphyrin complex in chlorophyll. The fact that these cells are able to 
synthesise haem testifies to the existence in these cells of all the factors 
necessary to carry the reaction through from the ubiquitously distributed 
precursors, glycine and succinyl CoA to haem, although, obviously there is a 
variation between cells in the amounts of haem they are able to produce. This 
implies a fine regulation of the biosynthetic pathway under physiological 
conditions such that there is a close coupling of haem biosynthesis with the 
synthesis of other compounds such as globin, which combine or conjugate with haem. 
Within the complex of the haem biosynthetic pathway there are various possible 
sites for its control. The initial and terminal stages of the pathway take place 
in the mitochondrion (Granick & Mauzerall, 1960; Sano & Granick, 1961) and the 
intermediate steps take place in the cytoplasm. The variety of enzymes 
catalysing these reactions and the compartmentalisation offer a number of sites for 
controlling the pathway.
The availability of glycine, succinate and/or succinyl CoA could 
potentially limit the rate at which haem is formed and some evidence for this has 
been advanced (De Matteis, 1967). This would seem unlikely however, since
probably less than 1% of all succinyl CoA formed in the cell enters this pathway, 
and in consequence alterations of the levels of succinyl CoA would represent an 
extremely inefficient method of control. Similarly the availability of both 
glycine and succinate in the cell is so large that alterations in the levels of 
either or both of these would result in a gross metabolic derangement in the cell.
The same applies to pyridoxal phosphate deficiency, although Elder & Mergel 
(1966) have shown that induced pyridoxine deficiency lowers porphyrin precursor 
excretion in patients with A.I.P. In these patients however, the pathway was 
already working at such a high level, as it is in all hepatic porphyrias, that 
it is much more vulnerable to attack in this direction.
The pathway could also be controlled by a separate metabolic sequence or 
cycle which breaks down ALA. This postulated cycle, the 'Shemin cycle', has 
already been discussed and has been shown to have no appreciable effect on this 
system.
Control of the activity of any of the other enzymes within the pathway 
could also theoretically take place, and actually occurs in pathological 
situations. In lead intoxication both ALA dehydrase and haem synthetase are 
inhibited (Chisholm, 1964),to such an extent that in severe lead poisoning there 
is a large build-up of both ALA and coproporphyrin in the urine. These facts 
have been used in the diagnosis of lead poisoning (Goldberg, 1968c).
In the porphyrias, the various patterns of porphyrin excretion can be 
explained by variations in the levels of enzymes within the pathway leading to 
different handling of excess ALA produced by ALA synthetase. In the 
erythropoietic porphyrias, the series I isomers of uroporphyrin and 
coproporphyrin are excreted in the urine. This can be explained by a low
activity of the uroporphyrinogen .synthetase (Booij & Rimington, 1957; Rimington
& Booij, 1957), thus limiting the production of series III isomer. In the
hepatic porphyrias there are other variations. In A.IP. mainly porphyrin 
precursors are excreted whilst in variegate porphyria, coproporphyrin III and
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protoporphyrin are excreted (Goldberg & Rimington, 1962). Again the cause 
probably lies in the fact that for normal concentrations of precursors the 
enzyme levels are adequate, but when challenged with increased levels of 
precursors, these activities become limiting within the pathway leading to a 
build-up of certain constituents. Thus there are three points which would 
suggest that in the normal metabolic situation, none of these three steps are rate 
limiting. Firstly there is no build-up of any intermediates in the pathway; 
secondly there is a high preponderance of the physiological type III porphyrin 
isomer over the type I isomer, showing the isomérisation stage to be non-limiting 
and finally most cellular homogenates can metabolise exogenous ALA to porphyrins 
but cannot convert glycine or succinyl CoA to porphyrins to any great extent 
(Granick & Urata, 1963; Saillen, 1963; Sardesai et al 1964; Levere & Granick 
1967). In addition, in the normal situation the pathway operates very 
efficiently both in humans (fig.17) and in rats (fig.1.3) This could only be 
attained by a very closely linked series of controls and is made all the more 
sensitive by the short half life of ALA synthetase at the primary control point 
of the pathway (Granick & Urata, 1963). In acute porphyria the balance becomes 
very much less efficient and about 40% of the intermediates are lost by excretion, 
(fig.18), From this figure it can be seen that in this particular hepatic 
porphyria. A,I.P. the greatest excretion is at the precursor level showing that 
these are being produced in great excess. Thus it is clear that the rate of 
formation of ALA, and the activity of ALA synthetase are prime determinants of 
the rate at which the haem biosynthetic pathway operates.
Since ALA synthetase is mitochondrial, it has been suggested that 
mitochondrial DNA rather than nuclear DNA codes for this protein. This would 
seem to be excluded in mammals,at least, by the autosomal dominant pattern of 
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mitochondrial DNA the pattern of inheritance would be maternal since sperm 
mitochondria cannot be transmitted to the ovum. The probability from recent 
work (Scholnick et al, 1969) is that like cytochrome C (Gonzales - Cadavid & 
Campbell, 1967; Kadenbach, 1967) ALA synthetase is synthesised in the 
cytoplasm and transported to the mitochondrion, since the majority of protein 
synthesis within the mitochondrion is structural rather than functional.
As shown previously ALA synthetase activity may be controlled by either 
end product inhibition or repression in bacteria. The normal low levels of 
enzyme together with its very much higher levels in porphyria and easy 
inducability indicate that in normal circumstances the enzyme is highly 
repressed. By the operon concept of Jacob & Monod (1961), as postulated for 
bacteria, it is suggested that a similar method of control applies to 
eucaryotic cells, using the repressor/operator mechanism whereby a defect in 
either the operator or regulator gene leads to a derepression or activation of 
the structural gene for ALA synthetase which leads to an overproduction of 
porphyrins and their precursors (fig. 19 )
The effect of various compounds such as the barbiturates on ALA synthetase 
are mediated by the 'de novo ' formation of ALA synthetase rather than the activation 
of a 'latent' form of the enzyme or by the depression of its rate of 
degradation, as evidenced by work using antibiotics. It has always been 
indicated that ALA synthetase is the rate controlling factor in the biosynthesis 
of haem and that its synthesis can be regulated by these substances. The work 
using the antibiotics cycloheximide and actinomycin D to block protein 
synthesis show that to induce ALA synthetase, an intact protein synthesising 
system is required. This system commences at the level of DNA. This nucleic 
acid codes for a messenger RNA. In collaborative work at present in progress 
it has been shown that in chemically porphyric states, an excess of this 
messenger RNA is produced.
C E L L



















Possible Scheme of control of the Haem Biosynthetic Pathway. OP. represents
the operator gene and Ql, 0 2 — ►  07 the Structural Oenes. mRNAj 
(messenger RNA) codes for ALA synthetase whilst mRNA® 2— #7 code for the 
subsequent enzymes (Eg— ^  Bf) of the biosynthetic pathway.
Haem is postulated to combine with the Aporepressor to form the repressor 
which functions at the level of the operator gene.
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In this work (Skea et al 1970) it has been shown that RNA extracted 
from the liver of a rat made porphyric with AI A with a resultant 10-fold increase 
in ALA synthetase activity (fig. 20) significantly elevates the activity of 
ALA synthetase in chick embryo liver culture. This elevation rises to a peak 
in about 4 hours and has disappeared after 8 hours (fig. 21). This activity 
appears to reside mainly in the lower molecular weight fractions of the RNA 
(fig.22) and these effects were abolished by cycloheximide and by incubation 
of the RNA with ribonuclease prior to putting it into the culture medium.
These results follow on from the work of Hickman et al (1967) who showed 
elevated porphyrins after 18 hours in a simpler culture system, although this 
work has not been able to be duplicated (Moore et al, 1969b),
This messenger RNA produces ALA synthetase which through the rest
of the biosynthetic pathway produces Haem. Haem in this model acts as a
repressor, combining with the aporepressor molecule to form an active repressor
which acts on the operator gene to prevent the function of the structural gene.
It is at this level that the various drugs and chemicals are postulated to act.
If these compounds combine with the aporepressor then,either by blocking the
binding site,or by alteration of the molecular configuration, this inactive molecule
can be formed. In this case the structural gene is derepressed and there is
an uncontrolled formation of ALA synthetase, and in consequence an
overproduction of the components of the pathway. The same effect would be
produced if these compounds acted on the regulator gene, which produces the
aporepressor, and lowered production of this aporepressor. Alternatively
this effect could be produced by a depression of the levels of haem available
for combination with the aporepressor molecule. In the case of the
barbiturates, it is known that they elevate the levels of cytochrome P.450
(Conney, 1967) and by this means stimulate both their metabolism and the
metabolism of other drugs. It is possible that by depressing haem levels
within the cell by their utilisation for cytochrome P,450 production, ALA 
synthetase is in fact induced, by the depressed levels of active repressor.
AIA
3 0 0 m g  kg for 7 days 
( 9 Rots : P < 0  0 0 1 )
RAT HEPATIC 
ALA SYNTHETASE ACTIVITY  






Fig.20 Hie effect of Intraperitoneal Allylisopropyl acetamide (AIA)
on rat hepatic ALA synthetase activity. Bars represent meant 
standard deviation. Activity is expressed as pg ALA produced 
per g Protein per hour.
RNA STIMULATION of PORPHYRINOQENISIS








Pig. 21. Porphyric Rat Hepatic RNA stimulation of ALA synthetase 
activity in chick embryo liver culture. Each point 
represents one culture. FRNA: Porphyric RNA,
N.RNA Normal RNA.
RNA FRACTIONATION EXPERIMENTS ( SEPHADEX 
(Mean ± S.D.)
ALA. S. ACTIVITY  







P. RNA N.RNA CONTROL H M H M
P. RNA N .R N A
Pig.22. The effect of rat hepatic RNA on ALA synthetase activity of chick 
embryo liver culture. P. RNA (Porphyric RNA) N. RNA (Normal RNA) 
and control (untreated) culture activities after preincubation of 
the cultives for 18 hours and treatment for 3 hours are shown in 
the first three bars. The subsequent 6 bars show the effect of the 
P.RNA and N.RNA after fractionation on Sephadex. G.lOO (H - Heavy,
M - Medium and L - Light fractions). The bars represent the mean 
± SD.
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Alternatively of course, the barbiturates could act in one of the other ways, 
raise ALA synthetase and hence haem, and by this means raise cytochrome P.450 
levels.
Another method of detoxication other than oxidation is by the 
formation of soluble conjugates. It has been shown that steroid glucuronides 
are ineffective as inducers of ALA synthetase while the free steroids are 
active as inducers. Within the body, steroids and other compounds are 
detoxicated by glucuronide formation from UDP glucuronic acid and by the 
enzyme UDP glucuronyl transferase.
In the hepatic porphyrias a high basal level of ALA synthetase is 
genetically determined and little is required to elevate these levels even 
higher into an attack. This would suggest in addition some deficiency in 
the normal repressor control of enzyme activity. In the first sections 
barbiturates, ethanol and some steroids were all implicated in the elevation 
of rat hepatic ALA synthetase by the 'de novo' production of this enzyme.
In the last section all attacks of hereditary co proporphyria were 
precipitated by one of these compounds, by the barbiturates for sedation and 
anaesthesia, sulphonamides for infection and ethanol. Also those patients 
in attack had elevated levels of steroids, and although these particular 
steroids have not been implicated in the steroids section as porphyrinogenic 
they could be metabolites of the porphyrinogenic steroids.
Steroids would seem to play an especially important role in the 
porphyrias. It is possible to relate these steroid effects to two of the 
factors involved in porphyrinogenesis. Ethanol has been shown to change 
the redox state of steroid sulphates, to raise androstenediol sulphate and 
lower DHA sulphate in human plasma (Cronholm &Sjovall, 1970). Diet also 
affects steroid levels. As shown earlier, diet plays a large part in
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porphyrinogenesis, with starvation raising the levels of ALA synthetase.
Hendrikx et al (1968) showed that starvation lowered KiA excretion; this could 
be related to an elevated level of DHA in the plasma which as has been shown 
earlier could increase hepatic ALA synthetase activity. The change in this 
system is an increase in the half life of DHA sulphate and these observations 
correspond well with the observation that ALA and PBG and porphyrin excretion 
levels rise during starvation in animals (Beattie, 1970).
Since steroids are the first endogenous factor to be implicated in the 
patho-rgenesis of the porphyrias, determinants such as impaired detoxication by 
glucuronide formation could represent an important ancillary mechanism in the 
exacerbation of the disorder 'in vivo' and possibly even play a more important 
role in the acquired porphyrias where the general mechanisms of detoxication are 
upset by foreign porphyrinogenic compounds. Thus a linking factor in the 
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ALA Synthetase Assay (micro) Assay 1.
Ref: Dowdle, et al (1967) as modified by M. R. Moore.
Reagents
1) Homogenisation Buffer 0.Q2M Na ED TA
0,15M tris
pH to 7.2 with HCl
2) Incubation Buffer 0.2M glycine
O.IM Na citrate 
pH 7.4
3) 0.3M I.e.A.
4) 0.6M Na acetate
5) Acetyl acetone
6) Special Ehrlichs Reagent.
METHOD
Remove liver rapidly from animal and chill in ice-cold homogenisation buffer 
immediately, rinsing to remove as much blood as possible. Take tissue, blot on 
clean adsorbent paper and dry, cut off aliquot, and weigh into a homogenisation 
vessel. Make 1 in 4 homogenate accurately (if working to weight reference) 
using piston homogeniser in cold (ten rapid strokes). Into micro polyethylene 
test tubes put lOOjil incubation buffer and lOOjil homogenate. Use three tubes 
per assay, incubated thus, stoppered in a covered water bath at 37°C for 1 hour, 
one stopped immediately by the addition of 200pl TCA and mixed. After 1 hour 
remove tubes, unstopper and stop reaction with 200pl TCA, mix and stand for 10 
minutes at QOC. Take tubes and spin in microfuge for 3 mins. From each tube, 
using a constriction pipette, remove a 200pl aliquot of supernatant solution and 
put/
- 110
put this into a boiling tube containing 200pl HgO, 50pl Na Acetate and 20pl 
acetyl acetone. Mix thoroughly and place in boiling water bath for 10 mins. 
Remove, allow to stand to cool and add 50pl H 2 O and SOOpl fresh cold Special 
Ehrlichs Reagent. Stand for 15 minutes and read at 552mp in microcells. 
Read ALA content from standard graph.
- I l l  -
A L . A. Synthetase - Method for whole liver homogenates. Assay 2.
This is a modification of the method of Marver et al, 1966.
Reagents.
(1) Homogenisation Buffer: 0.9% NaCl (Saline) pH 7.4
O . S m M E D T A (0.1461g/litre)
10.0 mM Tris (1.2114g/litre)
(2) Incubation Mixture: 100 mM glycine (7.505g/500ml) pH 7.2
50 mM Tris (6.0570g/500ml)
6.6 mM EDTA (1.9289g/500ml)
2N HCl 
2N NaOH
0.5 M Phosphate Buffer pH 7.0 
0.1 M HCl/4M NaCl 
0.2 M HC1/4M NaCl
Acetyl Acetone
Methanol: glacial acetic acid (2:1) (MeOH/HAC)
0.01 M ammonia in n. Butanol (BUOH/NH^OH)
Dowex 2 x 8  Cl~
Special Ehrlich's Reagent
METHOD.
Remove liver rapidly from the rat, chill in ice cold homogenisation buffer, blot, 
and weigh out 2 - 3 g. aliquot for homogenisation. Make an accurate 3 i 1 
homogenate with homogenisation buffer using 10 strokes of a Potter homogeniser, 
keeping cold all the time. Take 3ml. incubation mixture, 1ml. homogenate in a 
25 ml. conical flask and incubate at 31°C for one hour in a rapidly shaking water 
bath. This stage should be carried out with 3 flasks, 1 zero time and 2 one 
hour samples. Stop the reaction by transferring the contents of the flask into 
a centrifuge tube containing 2 ml 2M HC1„ Stand for 15 minutes at room 
temperature and then centrifuge for 4 minutes at 2000 g. Decant into fresh 
tubes containing 1.55 ml 2M NaOH and 0.4 ml 0.5 M Phosphate Buffer, Wash ppt, 
once/
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once with distilled water and transfer the washings to the tube. Adjust the pH
of this solution to 6-6.5 using 2M NaOH, add 0.1 ml acetyl acetone, shake and
place in boiling water bath for l-minutes. Cool the tubes and add 2 ml 
0.2MH HC1/4M NaCl.
This solution is then put on to a column prepared thus:-
Take columns, 20 cm x 1 cm,, pack base with cotton wool plug and put in a
slurry of Dowex 2 x 8  200 - 400 mesh to give 1 cm. packed resin, wash this,
then add 5 ml 0,IM HCl/4M NaCl followed by a wash with 5 ml distilled water.
The column is now ready for use. When the solution has been put on to the 
column, the amino-acetone pyrole is eluted with 2ml BuOH/NH^OH followed by a 
wash with 5 ml of the same. The ALA pyrole is then eluted with 1.5 ml 
MeOH/HAC then 0.4 ml the same into 5 ml stoppered measuring cylinders. This
solution is made to 2 ml^ 1 ml special Ehrlich’s reagent added, shaken 
thoroughly and allowed to stand for 15 minutes before reading at 555mp. The
readings are converted from a standard graph.
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ALA Dehydrase - Method
Solutions 0.15M KCl
0.6 M KCl
Phosphate Buffer pH 6.8
0.0307 g glutathione in 20ml buffer (GSH) 




Take 10 ml fresh blood and put into a heparinised bottle, shake, then spin blood 
at 2,SOOrpm for 20 minutes at 4°C. Remove the serum and wash cells with 
0.15M KCl, spin at 2, SOOrpm for 10 minutes at 4°C and remove KCl wash.
Take 2 ml packed R. B. 0., make up to 10ml with 0.15M KCl, shake well to mix and 
place 1 ml sample in a tube for an R. B.C. count. Spin again at 2,500 r.p.m. 
for 10 minutes and remove KCl. To the packed cells add 5.4 ml distilled water 
and leave for 20 minutes on ice to Haemolyse. Add 1.8 ml 0.6M KCl, mix and put 
in bath at 37°C, *Take Thunberg tubeandadd 2 ml G 8 H. solution and 0.1 ml 
ALA solution, and equilibrate in bath.
Heat at 37°C for % hour to equilibrate temperatures, pipette 1 ml haemolysate
into Thunberg tubes, then evacuate at the water pump and mix the tube contents. 
The 0 time samples are put into 2 ml 0.3M TCA immediately to stop the reaction. 
The other tubes are heated at 37°C shaking for 1 hour, and then poured into 
2ml/
* For tissues use a whole homogenate of tissue in 0.15 MKCl and start here
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2ml 0.3M TCA to stop the reaction. The solution was spun to remove precipitate, 
the supernatant decanted, and again spun to remove further precipitate.
Pipette off 2 ml and to this add 2 ml special Ehrlichs reagent. Spin to remove 
white ppt and read after 15 minutes at 553 m|i. This can be done up to % of an 
hour.
NOTE: Times and temperature are important and all glassware must be metal ion
free, i.e. acid washed.
Calculation
OD X 1.47 .Q
-------  = units ALA dehydrase/10 RBC/hr
cell count
Cn moles PBG)
RNA. DNA (Ceriotti 1953,1955) and PROTEIN (Lowry et al 1951) - METHOD FOR LIVER.
Reagents 2% Na2C03 in 1 N NaOH : - A
0.5% CUSO45H2O in 1% Na K Tartrate : - B 
Solution C 50:1 A:B 








Take 1 lobe of liver, weigh and make a 1/20 homogenate in ice cold water. Take 
an aliquot of this homogenate and dilute it to a 1/50 homogenate for protein 
estimation, which is done by taking a 1 ml sample, adding 5 ml reagent C and 
standing for 10 minutes. Take this and add 0.5ml reagent E mixing immediately 
and thoroughly. Stand this for at least 30 minutes and read the samples against 
a blank at 750mp. This gives protein, from a standard graph.
For nucleic acids, take 5 ml 1/20 homogenate, add 2.5ml 0.6N HCIO4, mix and stand 
for 10 minutes at 0°C. Centrifuge this in the cold at 2000g for 5 minutes, discard 
supernatant, and wash precipitate twice with 0.2N4HCIO . Drain the tubes and add
4 ml 0.3N KOH and incubate the tube at 37° shaking for one hour, ensuring that the 
precipitate is dissolved. After incubation cool and add 5 ml 0.6N HCIO4 and stand 
for 10 minutes in the cold. Centrifuge at 2000g for 10 minutes and remove 
supernatant to 100 ml. cylinder for RNA estimation, wash precipitate twice with
5 ml 0.2N HCIO4 keeping washings for RNA estimation. For RNA estimation, take
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supernatant and washings, and make up to 100 ml. This solution is then read at 
260 mp for RNA.
For DNA estimation, redissolve the precipitate in 5 ml 0.3M KOH, transfer to a 
25 ml cylinder, add a further 3 ml 0.3 M KOH and make up to 25 ml with H^O.
Take 2 ml of this solution add 1 ml indole solution, 1 ml cone HCl and put in 
boiling water bath for 10 minutes. Cool and extract this solution with 
chloroform until no more pink colour can be extracted. Read the OD of the
upper layer at 490 mp for DNA from standard graph.
Reduced Glutathione in Blood.
Ref: Beutler et al (1962)
Reagents
1) Precipitating solution 1.67g metaphosphoric acid
0.2g disodium EDTA 
30.Og NaCl
All made up to 100ml in distilled water. 
Store cold.
2) Phosphate Solution 0. 3M NagHPO^ in distilled water.
3) DTNB Reagent (o.040g 55’dithiobis 2 nitrobenzoic acid made up to 
lOOmls in 1% Sodium Citrate. )
Procedure.
Put 0.2ml blood into 1.8ml distilled water and then add 3ml precipitating
solution to the haemolysate. Allow to stand for 5 mins. and centrifuge at lOOOg for
10 mins. in cold.
Take 2ml supernatant and add to 8ml phosphate solution. Add 1ml DTNB reagent, 
mix well and read at 412 mp within 5 mins.
For standards do not use a GSH concentration of greater than 100mg%.
Dissolve GSH in 2 : 3^H20:ppt. soln.
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Porphyrin Precursors
ALA AND PBG TECHNIQUE
Ref: Mauzerall and Granick (1956) as described by Haeger Aronsen (1960)
PRINCIPLE - In contrast to ALA, PBG is retained by the anion-exchanger Dowex 
2 in the acetate form. ALA, however, is retained by the cation-exchanger Dowex 
50 in the hydrogen form.
After elution from the ion-exchangers, PBG and ALA are demonstrated by means of 
p-dimethylaminobenzaldehyde (DMAB), the former substance directly; the latter 
after quantitative conversion to the 3-acetyl-2-methylpyrrole 4-(3') propionic 
acid by heating with acetylacetone. With DMAB in acid solution, PBG as well as 
the pyrrole obtained on condensation of ALA and acetylacetone, forms coloured 
complexes, which are spectrophotometrically determined.
REAGENTS
Dowex 2 - X 8, 200 - 400 mesh - Preparation: The ionexchanger is placed in
water and allowed to sediment after which the water is sucked off. The 
washing is repeated until the supernatant is clear. The exchanger is then 
prepared on a column, first by conversion to the acetate form by washing with 
3 M sodium acetate until the eluate is chloride-free (as tested with silver 
nitrate). It is then washed with water until the washings are neutral (as 
tested with litmus paper). The ion-exchanger is stored in about twice its 
volume of water in a covered vessel. Stored in this way it will keep for at 
least 3 - 4  months at room temperature.
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Dowex 50 - X 8, 200 - 400 mesh. - Preparation: The finest particles are
separated off by repeated suspension and sedimentation in water. The ion­
exchanger is converted to the sodium form during about 20 hours' storage in 
twice its volume rf 2 N sodium hydroxide, after which it is washed with water 
until the washings are neutral. It is then reconverted to the acid form by 
treating alternately with about 1 volume of 4 N hydrochloric acid and 6 volumes 
of 2 N hydrochloric acid. The exchanger is stored in twice its volume of 1 N
hydrochloric acid in a covered vessel. It will then keep for at least 3 - 4
months at room temperature.
Acetic acid 1 N and 0.2 N 
Sodium acetate - M
Acetate buffer, pH 4.6 - 57 ml of glacial acetic acid and 136 g. of sodium
acetate trihydrate are diluted with water to 100 ml.
Acetylacetone.
Ehrlich's reagent I. - 2 g. of p-dimethylaminobenzaldehyde and 100 ml. of 6 N 
hydrochloric acid.
Ehrlich’s reagent II. - 1 g. of p-dimethylaminobenzaldehyde is dissolved in 
about 30 ml of glacial acetic acid and 8 ml. of 70% perchloride acid S. G. 1.7 in 
a 50 ml volumetric flask, after which the solution is diluted to the 50 ml. mark 
with glacial acetic acid (N.B. Will keep only for about 6 hours).
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ALA AND PBG TECHNIQUE
COLLECTION OF SAMPLE - PBG is labile and is therefore preferably determined 
on freshly voided urine. However, if it is necessary to store the urine before 
analysis, it should be done at a pH of about 7 - 8  (alkalinised with sodium 
carbonate) and a temperature of about4- 4°C., in the dark. ALA on the other hand, 
will keep for at least 20 days at pH 4 - 6 and a temperature of about + 4^0.
When added to the Dowex 2 column, the pH of the urine should be 4 - 7.
ANALYSIS - Chromatographic columns, about 1 by 10 cm. are used for these
analyses. Cotton wool plugs are placed in the bottom. The columns are then
packed by sedimentation of the ion-exchangers to a level of 2 - 3 cm. Filter
papers are placed at the top. Each PBG determination requires 1 Dowex 2 column;
each ALA determination 1 Dowex 2 and 1 Dowex 50 column. Before the columns are 
used, they are rinsed in water, Dowex 2 with about 5 ml and Dowex 50 with about 
25 ml.
Exactly 1 ml. of urine is placed on a Dowex 2 column. After urine has passed 
through the column at a flow rate of about 6 drops a minute into a test tube
(A), the column is washed twice, each time with 2 ml of water. The washings
are collected together with the urine in A, which is then set aside.
PBG is eluted from the Dowex 2 column with 2 ml of 1 N acetic acid and after
this has passed through, with 2 ml. of 0.2 N acetic acid. The combined 
eluates are collected in a 10 ml. volumetric flask and diluted to the mark 
with water.
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2 ml of Ehrlich’s reagent I is added to a 2 ml. aliquot of the well mixed PBG
solution. If the result is positive, a pink to cherry-red colour rapidly
develops. The extinction is read after exactly 5 minutes in a
spectrophotometer, at 555 m)i and a 1 cm. cuvette. An equal volume of
Ehrlich's reagent I and water is used as a blank.
The contents of A are quantitatively transferred to a Dowex 50 column. The 
urea is removed from the ion-exchanger with about 30 ml. of water. (If the 
eluate contains urea, a bright lemon-yellow colour will develop on mixture with 
an equal volume of Ehrlich's reagent I). The ion-exchanger is then washed with
3 ml. of 0.5 M sodium acetate. After draining, a 10 ml. volumetric flask is
placed under the column, after which a further 7 ml. of M sodium acetate is
allowed to pass. 0 .2ml. of acetylacetone is added directly to the flask and the 
mixture is shaken thoroughly. The solution is afterwards diluted with acetate 
buffer, pH 4.6 up to the mark. The entire quantity of fluid is transferred to a
15 ml. glass-stoppered test tube, which is then placed in boiling water for 10 
minutes and subsequently cooled to room temperature.
To 2 ml. of this solution is added 2 ml. of Ehrlich’s reagent II. If the test 
is positive, a pink to cherry-red colour will successively develop. The 
extinction is read after exactly 5 minutes in a spectrophotometer, at 553 mp and 
a 1 cm cuvette. The blank consists of 7 ml. of 0.5 M sodium acetate, treated
in the same manner as the Dowex 50 eluate.
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Porphyrins Ref: Rimington (1961)
URINARY COPROPORPHYRIN AND UROPORPHYRIN
Principle.
Coproporphyrin and any coproporphyrinogen are first extracted by ether containing 
acetic acid. Coproporphyrinogen is oxidised to porphyrin by shaking the solution 
with dilute iodine. The total coproporphyrin is then transferred to 5% 
hydrochloric acid and determined spectrophotometrically using a formula to correct 
for absorbing impurities. Uroporphyrin is removed from the residual urine, plus 
washings of the ether phase, by adjusting to pH. 1.5 and shaking with 
cyclohexanone. After addition of ether it is transferred to 5% hydrochloric 
acid and determined spectrophotometrically using a correction formula as in the 
case of coproporphyrin (Dresel, Rimington and Tooth, 1956).
Materials required.
Ion-free distilled water for preparing reagents and for all manipulations. 
Acetic acid (glacial).
Ether: anaesthetic grade, free from peroxides. Less pure ether may
be stored in dark bottles over powdered ferrous sulphate with which it 
is occasionally shaken vigorously, When required, the decanted ether is 
washed twice with distilled water (about^ of its volume each time) and 
used without drying.
Cyclohexanone: technical grade redistilled in vacuo to obtain
colourless fraction with constant B. P.
Dilute sodium acetate solution: 30 g. of sodium acetate hydrated
(ANALAR) dissolved in water and made up to 1 1., solution filtered.
Dilute iodine solution, 0.005%. This is prepared freshly for each 
day’s use by diluting 1 ml. of a stock solution of 1 g. iodine 
(resublimed) in 1 0 0 ml. of absolute ethanol with distilled water to 
make 200 ml. The stock solution Is stable if kept at 5°C. in the 
dark.
Hydrochloric acid (approx. 5 g/100 ml.) : 120 ml. concentrated




The concentration of porphyrin in the fresh urine specimen is first ascertained 
roughly by the qualitative test described in Broadsheet No.20. The volume 
taken for the determination is based upon this result. Of an apparently 
normal urine, take 25 ml.; if fluorescence is very intense, 2-5 ml., diluted 
to 25 ml. with distilled water, will suffice. The sample is accurately 
pipetted into a separating funnel, water added to make 25 ml., if necessary, 
and 2.5 ml. of glacial acetic acid is added followed by 50 ml. of ether. The 
mixture is shaken vigorously (i.e. about 2 0 0  times) for 1 min..and after the 
phases have separated, the lower (aqueous) phase is run into a second 
separating funnel and shaken similarly with 50 ml. of ether. This ether
extract is combined with the first and the coproporphyrin-free aqueous phase
(U) retained for determination of uroporphyrin.
The combined ether extracts are washed in the separating funnel by shaking for 
1 min, as follows:-
1 . Successively with 20 ml. portions of dilute sodium acetate solution 
until the aqueous phase no longer shows red fluorescence. Normally, 
two shakings should suffice. These washings are combined, twice 
shaken for 1 min. with an equal volume of fresh ether to recapture 
any coproporphyrin which may have been carried over (this ether is 
added to main bulk) and then added to urine residue, U.
2. Once with 50 ml. of 0.005% dilute iodine solution.
3. Once with 25 ml. of distilled water.
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Uroporphyrin, present in U, the urine residue plus washings of the ether phase, 
is recovered by adding cone, hydrochloric acid to pH 1.5 (pH meter). Measure 
the volume and shake for 2 min. thoroughly but not too vigorously with two 
successive portions (each V/2) of cyclohexanone, allowing good separation of the 
phases. To the combined cyclohexanone extracts add a volume (2V) of ether and 
mix. Occasionally a small quantity of aqueous phase separates at this stage 
but it should not be removed from the funnel. The uroporphyrin is extracted by 
shaking with successive small volumes (1 .5 -2ml.) of 5% hydrochloric acid until 
the extract no longer shows red fluorescence under ultra-violet light. The 
extracts are conveniently collected in a graduated measuring cylinder, mixed 
and their total volume recorded. This solution is filtered or centri&uged and 
the optical density is measured at 430 mp, 380 mp, and at the peak of the Soret 
band (about 405 mp) and uroporphyrin content calculated as follows
Calculation.
If V = vol. of urine taken,
V = vol. of acid extract,
D. 430 = optical density at 430 mji.
D 380 = optical density at 380 mp,
D max. = optical density at the peak of the Soret band,
then [2D max. - (D 4 3 0 + D 380)] x 832 x pg, uroporphyrin/1 .
Y
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Coproporphyrin is now extracted by shaking the ethereal solution with 
successive 2 ml. portions of 5% hydrochloric acid until the extract no longer 
shows red fluorescence under ultra-violet light when viewed in a thin-walled 
tube. The extracts are conveniently collected in a graduated measuring 
cylinder, mixed, and their total volume recorded. This solution is filtered or 
centrifuged and the optical density is measured in a 1 cm. cell at 430 mp, 380 mp 
and at the peak of the Soret band (about 401 mu), and coproporphyrin content 
calculated as follows:-
Calculation:
For derivation of the formula used to correct for impurities having spectral 
absorption in the Soret band region, see Rimington and Sveinsson (1950);
Holti, Rimington, Tate and Thomas (1958).
If V = vol. of urine taken,
V = vol. of acid extract,
D 430 = optical density at 430 mp
D 380 = optical density at 380 mp
Dmax. = optical density at peak of Soret band, 
then [2D max. - (D 430 + D 380)] x 837 x ^-pg. coproporphyrin/l.
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FAECAL COPROPORPHYRIN AND PROTOPORPHYRIN
Principle
Ether soluble porphyrins and porphyrinogens are extracted by ether containing 
acetic acid. Porphyrinogen is oxidised to porphyrin by shaking with a dilute 
solution of iodine. Coproporphyrin is then transferred to 0.1 N hydrochloric 
acid and protoporphyrin to 5% hydrochloric acid. Pigments derived from 
chlorophyll remain in the ether phase.
METHOD
The sample is well mixed with a glass rod or otherwise and two portions each of 
about 0. 5 g. weighed accurately into the tared weighing bottle and stoppered 
tube respectively. The moisture content of the sample is determined by heating 
the weighing bottle and contents at 105^ until constant in weight (about 4 hours).
To the boiling tube is added about 2 ml. acetic acid, and the sample 
disintegrated by shaking and stirring, if necessary, with the glass rod. About 
20 ml. of ether is added and the mixture shaken vigorously for 1 min. The 
extract is cleared by light centrifugation (about 2000 r.p.m. for 3 mins.) and 
transferred to a large measuring cylinder (250 ml.).
The faecal residue is extracted repeatedly with acetic acid and ether in exactly 
the same manner until the extract no longer shows fluorescence under ultra­
violet light. The volume of the combined ether extracts is recorded and either 
the whole or an aliquot portion (depending upon the intensity of red fluorescence 
is transferred to a separatory funnel. It is washed twice by shaking for 1 min. 
with 25 ml. of dilute sodium acetate solution. The combined washings are twice 
shaken for 1 min. with 25 ml. of fresh ether to recapture any porphyrin which 
may have been carried over (this ether is added to the main bulk) and are then 
reserved for examination for uroporphyrin. The ether is then shaken with about 
one-fifth of its volume of dilute iodine solution and finally with 25 ml. of water.
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Coproporphyrin is now extracted by shaking with successive small quantities 
(2 ml.) of 0.1 N hydrochloric acid until the extract no longer shows red 
fluorescence in ultra-violet light. The extracts are conveniently collected 
in a graduated measuring cylinder, mixed, and their total volume recorded. 
Optical density of this solution is measured at 430 mp, 380 mp, and at the 
peak of the Soret band (about 401 mp) and coproporphyrin content calculated 
as follows: -
Calculation.
If A = weight of faeces taken for extraction,
W = wet weight taken for moisture determination,
w = dry weight found in moisture determination,
V = volume of acid extract,
D 430 = optical density at 430 mp,
D 380 = optical density at 380 mp,
D max. = optical density at peak of Soret band,
then £ 2 0  max. - (D430+D380)] x 0.730 x V x W
A w
= pg. coproporphyrin/g. dry weight.
Protoporphyrin is extracted from the etheral solution after all coproporphyrin 
has been removed from the latter. This is done by shaking with successive 
small quantities (2ml.) of 5% hydrochloric acid until the extract no longer shows 
red fluorescence in ultra-violet light. Any fluorescence persisting in the 
ether layer is due to pigments derived from chlorophyll. The acid extracts are 
conveniently collected in a graduated measuring cylinder, mixed and their 
volume recorded. Optical density of this solution is measured at 430 mp,
:380:mp/
380 rap,, and at the peak of the Soret band (about 407 mp) and protoporphyrin 
content calculated as follows:-
Calculation.
If A = weight of faeces taken for extraction,
W = wet weight taken for moisture determination, 
w = dry weight found in moisture determination, 
V = volume of acid extract,
D 430 = optical density at 430 mp,
D 380 = optical density at 380 mp,
D max.= optical density at peak of Soret band,
then [SD max. - (D430+ D380)] x 1.226 x V x W
A V
= pg, protoporphyrin/g. dry weight.
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TISSUE UROPORPHYRIN, COPROPORPHYRIN AND PROTOPORPHYRIN
Tissue porphyrins are measured as per faecal porphyrins, the tissue sample is 
taken weighed and homogenised in glacial acetic acid In a piston homogeniser, 
ether added, homogenised again and the method continued as given before.
For the uroporphyrin content the remaining tissue pellet after centrifugation 
is homogenised in 0. IM NH4 OH. to which extract the sodium acetate washings 
are added from the previous ether treatment. This solution is used in the method 
described for urine. For tissues wet weight/dry weight ratio is taken as 1 and 




2.5g p. Dimethylaminobenzaldehyde (pDMAB)
0.5g HgCl2 Dissolved in loml glacial acetic acid. 
Perchloric Acid S.G. 1.7.
Glacial Acetic Acid.
METHOD
Dissolve pDMAB in about 50ml glacial acetic acid, add 24.5ml Perchloric acid, 
and 4ml HgClg solution. Mix, cool and make up to 1 0 0ml with glacial acetic 
acid in a volumetric flask.* Store in a dark bottle at 0°C.
♦ If at this stage any brown colouration appears, the reagent must be 
discarded.
(2) PORPHYRINOGENIC DRUGS.
DRUGS BELIEVED TO PRECIPITATE PORPHYRIA




Apronal (Sedonnid (1 )
Sex Hormones (1)
Oral Contraceptives (1 )
Phenytoin & Other Hydantoins (1) 




Chlordiazepoxide (Librium) (1 ) 
























Hydrocortisone NaSuccinate (Efcortelan) (14) 
Dichloralphenazone (Welldorm) (11) 
MethylDOPA (11)
Ethanol (14)
Steroids C19 & C21 (13,14)
DRUGS BELIEVED SAFE IN PORPHYRIA
1: Clinical Evaluation 2: 'In Vitro' & 'In Vivo' Evidence
Pethidine (9) 
Morphine (9) 
Mefenamic acid (9) 
Asprin (6 ) 
Chlorpromazine (9) 
Chloral Hydrate (8 ) 
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